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ABSTRACT OF THE DISSERTATION
Iron Dysregulation and Inflammation in Alzheimer’s Disease
by
Shino D. Magaki
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, May 2007
Wolff M. Kirsch, Chairperson
Alzheimer’s disease (AD) is the most common form of senile dementia in the US
and worldwide but the causes of its pathogenesis are currently unknown. In this study, we
examined two processes that have been implicated in the early stages of AD and other
forms of neurodegeneration, iron dysregulation and inflammation, both of which can
promote the increased production of amyloid precursor protein (APP). We have measured
different pools of brain iron in transgenic iron regulatory protein 2 knockout (IRP2-/-)
mice in the early stages of neurodegeneration and in affected brain regions from AD
patients at different stages of the disease. IRP2-/- mice demonstrated a region specific
deficiency in the metabolically active iron pool, loosely bound iron, at the youngest age
examined but not at an older age. A decrease in loosely bound iron was also observed in
the hippocampus of mild-moderate and severe AD patients. However, when IRP2
expression with respect to the hallmark lesions of AD, amyloid plaques and
neurofibrillary tangles (NFTs), was evaluated by immunohistochemistry, no significant
differences were found in the intensity of expression or localization of IRP2 between
control and AD brains. Thus, a functional iron deficiency was seen before and at the early
stages of neurodegeneration in both IRP2-/- mice and AD patients, but the disturbance in
human brains did not appear to stem from altered IRP2 expression.

xi

In the second part of the study, we detected inflammatory changes prior to the
manifestations of clinical AD by immunophenotyping leukocytes and examining their
cytokine production, as well as APP and Ap expression, in subjects with mild cognitive
impairment (MCI), a preclinical stage of AD. The production of the inflammatory
cytokines IL-6, IL-8 and IL-10 were increased in stimulated peripheral blood
mononuclear cells (PBMCs) from MCI subjects compared to healthy elderly controls.
Moreover, APP lymphocyte expression was elevated and an increased proportion of
lymphocytes with a concomitant decrease in the proportion of granulocytes were found in
MCI subjects.

In summary, functional iron deficiency and a tendency toward an

inflammatory phenotype were demonstrated to characterize the early stages of
neurodegeneration and AD.

xn

CHAPTER ONE
INTRODUCTION
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common senile dementing disorder,
affecting 18 million out 37 million demented people worldwide. In the US, direct care
alone for the 4.5 million AD patients costs $100 billion per year and the number of cases
is expected to rise as the population ages (Mount & Downton, 2006). The disease is
characterized by progressive memory loss and cognitive decline, and in the later stages,
motor and sensory impairment (Mott & Hulette, 2005). Age is the greatest risk factor,
insofar that the prevalence of AD doubles every five years after 60, with approximately
1% at age 60 to over 40% after the age of 85 (Mount & Downton, 2006; Townsend &
Pratico, 2005). The causes and pathogenesis of AD are still unknown, and definite
diagnosis is still dependent on neuropathologic examination of autopsied brain. The
characteristic hallmarks of AD are the presence of amyloid plaques, neurofibrillary
tangles (NFTs), cerebral amyloid angiopathy (CAA) and neuronal and synaptic
degeneration in vulnerable regions of the brain (Blennow et ah, 2006; Mott & Hulette,
2005). Amyloid plaques are composed of extracellular deposits of aggregated (3-amyloid
(A(3) peptide generated from the cleavage of a larger transmembrane protein, amyloid
precursor protein (APP), by proteolytic enzymes called p- and y-secretases (Mott &
Hulette, 2005). Normal processing of APP produces a heterogeneous pool of Ap peptides
39-43 amino acid residues long of which there are two predominant forms, the major
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soluble species of 40 amino acids, A(340, and the more fibrillogenic form of 42 aa, A(342
(Huang et al., 2004b). NFTs are formed from the accumulation of abnormally
hyperphosphorylated tau, a microtubule associated protein which normally functions to
stabilize the neuronal cytoskeleton. Genetically, AD is a heterogeneous disorder with
approximately five percent of cases consisting of early onset familial AD (FAD), which
has an autosomal dominant inheritance, while the remaining 95% is sporadic. Mutations
that cause FAD such as those in the presenilinl (PSEN1) and presenilin 2 (PSEN2) genes,
products of which are necessary for y-secretase cleavage of APP to A|3, increase AJ342
production (Wolfe et al., 1999). Other mutations include those in APP promoter regions
or duplications of the APP locus that increase APP production (Blennow et al., 2006;
Rovelet-Lecrux et al., 2006; Theuns et al., 2006). Moreover, individuals with Down’s
syndrome (DS) who have an extra copy of the APP gene, located on chromosome 21,
overexpress APP several-fold in the brain and show amyloid plaques at younger ages
(Rumble et al., 1989). Almost all cases of DS over 40 years of age develop AD (Neve et
al., 2000). However, the only confirmed genetic risk factor for sporadic AD is the
apolipoprotein E (APOE) b4 allele, with the presence of each copy lowering the age of
onset by about 10 years (Corder et al., 1993), although the mechanism by which ApoE, a
brain cholesterol transporter, increases disease risk is unclear (Blennow et al., 2006).

Regulation of APP
Overexpression of APP in certain regions of AD and DS brain suggests that
altered regulation of APP expression and processing may play a major role in disease
pathogenesis (Bellingham et al., 2004; Johnson et al., 1990). APP is a ubiquitously
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expressed single pass transmembrane metalloprotein found in most cell types on the cell
surface, endoplasmic reticulum and trans-Golgi and is composed of a 590-680 aa
extracellular domain and a ~55 aa cytoplasmic tail containing intracellular trafficking
signals (Rogers & Lahiri, 2004; Wilson et ah, 1999). APP can be processed either along
the non-amyloidogenic or amyloidogenic pathway. In the non-amyloidogenic pathway, asecretase cleaves APP to release soluble forms of APP, while in the amyloidogenic
pathway, processing by (3- and y-secretases produces A(3 that aggregate to form the
characteristic amyloid plaques in AD (Kienlen-Campard et al., 2002). The physiological
function of APP is unclear, but it has been shown to contain copper binding domains as it
was initially identified as a redox-active copper-zinc binding protein, and is postulated to
play roles in neuronal adhesion and copper metabolism (Rogers et al., 1999). Decreased
levels of copper have been reported in the brains of AD patients (Deibel et al., 1996) and
of transgenic mice overexpressing APP (Maynard et al., 2002) while higher levels of
copper have been demonstrated in APP knockout mice (White et al., 1999). Thus,
overproduction of APP and Ap is hypothesized to pool copper into the extracellular space
from the intracellular compartment and cause a deficiency of metabolic copper, which
may contribute to the pathology seen in AD brain (Bayer & Multhaup 2005; Maynard et
al., 2002).
The production and processing of APP is modulated by both intracellular iron
levels and cytokines (Reznichenko et al., 2006; Cacquevel et al., 2004; Rogers et al.,
2002; Amara et al., 1999). The 5’- untranslated region (UTR) of the APP mRNA contains
an iron regulatory element (IRE) to which iron regulatory proteins (IRPs) bind in order to
regulate its translation in response to fluctuations in intracellular iron levels (Rogers et
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al., 2002). APP synthesis has been shown to be downregulated in response to treatments
with iron chelators such as deferoxamine (DFO) and (-)-epigallocatechin-3-gallate
(EGCG), which can be reversed by the addition of iron (Reznichenko et ah, 2006; Rogers
et ah, 2002). In addition to an IRE, the 5’ - UTR of APP mRNA also contains an
interleukin-1 (IL-1) responsive acute box domain, through which IL-la and IL-1(3 were
found to upregulate APP translation in astrocytes (Rogers & Lahiri, 2004; Rogers et al.,
1999) and increase APP transcription in neurons (Forloni et al., 1992). IL-1 is an
inflammatory cytokine known to activate astrocytes to produce IL-6 and tumor necrosis
factor-a (TNF-a) (Cacquevel et al., 2004; Lee et al., 1993), and has been found
associated with plaques in AD brain (Griffin et al., 1995). Intra-cerebral injection of IL1(3 has been demonstrated to cause overexpression of APP in rat brain (Sheng et al.,
1996) while IL-la, IL-1 (3 and TNF-a have been reported to increase APP protein
expression in astrocytic cells and IL-6 found to stimulate APP gene promoter activity in
neurons (Lahiri et al., 2003; Ge & Lahiri, 2002; Del Bo et al., 1995). In turn, A(3 peptide
treatment in vitro, in cultured astrocytes and microglia (Del Bo et al., 1995), or in vivo.
by intra-cerebral injection into rat brain, induced IL-1 (3 production (Heneka et al., 2002).
Furthermore, A(3 was demonstrated to increase the production of IL-6 by rat primary glial
cells (Holmlund et al., 2002) and TNF-a by microglia (Szczepanik et al., 2001), both
cytokines found elevated in the brain and circulation of AD patients (Cacquevel et al.,
2004; Fillit et al., 1991).
As APP expression is ubiquitous, it is not surprising that extraneural increases in
APP expression have been observed in AD. Leukocytes and platelets have been shown to
express APP mRNA and protein (Bullido et al., 1996; Schlossmacher et al., 1992; Allen
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et al., 1991; Bush et al., 1990), and APP expression on lymphocytes and monocytes can
be increased with activating signals (Li et al., 1999; Bullido et al., 1996). Individuals with
Down’s syndrome (DS) show approximately 1.5 fold higher lymphocyte APP expression
than age-matched controls, consistent with gene dosage (Pallister et al., 1997). Moreover,
APP mRNA in PBMCs and APP protein in lymphocytes and monocytes have been found
elevated in AD patients compared to controls (Jiang et al., 2003; Jung et al., 1999). The
increase in APP expression in both AD patients and individuals with DS suggests that
changes in APP production and processing in peripheral immune cells may reflect
dysregulation of APP metabolism in the brain (Jiang et al., 2003; Jung et al., 1999;
Pallister 1997). Transgenic mice chronically expressing human APP have decreased
lymphocyte proliferation and production of cytokines in response to A(3 (Monsonego et
al., 2001). Together with the finding that lymphocytes from AD patients are less
responsive to stimulation with APP peptides compared to controls (Trieb et al., 1996),
this could implicate that chronic Ap exposure could lead to cellular immune
hyporesponsiveness to Ap and exacerbate its accumulation in AD (Sala et al., 2003). It is
well known that immune functions are compromised in AD patients, and exposure to
different antigenic epitopes or higher concentrations of APP may lead to T cell anergy in
AD (Trieb et al., 1996). Peripherally expressed APP could also potentially be a source for
abnormal amyloid deposited in the brain as well as extraneural organs and has additional
implications in the search for disease biomarkers (Pallister 1997; Joachim et al., 1989).
Thus, increased iron and inflammatory cytokines can elevate APP production and
promote Ap fibrillogenesis which may lead to increased Ap deposition and the eventual
formation of amyloid plaques. This in turn could increase cytokine production, and by
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association with iron, elevate free radicals and oxidative stress in a vicious cycle,
eventually triggering events resulting in the hyperphosphorylation of tau, microtubular
destabilization and disturbed axonal transport, and ultimately neuronal injury in AD
(Figure 1) (Ong & Farooqui, 2005).

Intracellular Iron Metabolism
Iron is an essential micronutrient, a necessary component of many proteins
involved in important cellular processes such as respiration and cell division.
Dysregulation of iron metabolism, resulting in either iron deficiency or excess, is
responsible for or implicated in an array of health problems including anemia, impaired
immunity and neurodegenerative diseases and is a major health problem worldwide
(Wallander et al., 2006). Approximately two thirds of total iron in the human body (4g in
an adult) is found in the hemoglobin of red blood cells which function in oxygen
transport, and 10% is in myoglobin (Halliwell & Gutteridge, 1984). Other heme iron
containing proteins include cytochrome P450 and cytochromes a, b, and c in the electron
transport chain (Levenson & Tassabehji, 2004). Non-heme iron consists of iron tightly
bound to proteins such as the iron transport proteins transferrin and lactoferrin and
enzymes such as prolylhydroxylase, cytochrome oxidase and tyrosine hydroxylase that
require iron for catalytic activity (Levenson & Tassabehji, 2004; Vranka et al., 2004;
Gutteridge, 1992). The remainder of non-heme iron is found in the intracellular storage
protein ferritin and hemosiderin (Gutteridge, 1992; Halliwell & Gutteridge, 1984).
Loosely bound iron is a labile, chelatable pool of non-heme iron that mediates the
transfer of iron from ferritin storage sites to where it is needed for enzymatic and
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Figure 1. Proposed schematic for the promotion of APP production, A(3 deposition and
amyloid plaque formation by cytokines and iron and vice versa in a vicious cycle,
eventually triggering events resulting in the hyperphosphorylation of tau and ultimately
neuronal injury in AD; n, neurons; a, astrocytes (Bayer et al., 2005; Cacquevel et ah,
2004; Bush, 2003; Lahiri et ah, 2003; Amara et ah, 1999; McGeer et ah, 2006).
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biosynthetic activity and consists of iron attached to phosphate esters, carbohydrates,
organic acids, DNA and membrane lipids (Kala et ah, 1996; Gutteridge, 1992). This iron
is thought to be responsible for catalyzing, via the Fenton reaction, the formation of
reactive oxygen species (ROS) including the highly reactive hydroxyl radical from
hydrogen peroxide, a normal metabolic byproduct (Halliwell & Gutteridge, 1984).
Hydroxyl radicals in turn can damage proteins, lipids and DNA. Indeed, the redox-active
metals, iron and copper, mediate the majority of ROS production (Ong & Farooqui,
2005).

An interesting feature of iron metabolism is that the body has no apparent method
of excreting excess iron other than losses through bleeding and sloughing of the intestinal
lining. Therefore, only about 1 mg/day of nutritional iron intake is necessary to maintain
iron balance, and larger intakes can lead to iron storage diseases over time. However, iron
metabolism in the brain is largely isolated from the rest of the body due to the bloodbrain barrier, and neither systemic overload nor deficiency of iron has a first-order effect
on brain iron concentration. The importance of iron for neuronal development and
function is attested to by the fact that iron deficiency in infancy can result in defective
development of the central nervous system (CNS) (Schenck & Zimmerman, 2004).
Neurons and glial cells need iron for many essential cellular functions including electron
transport, NADPH reductase activity, myelination of axons and as a cofactor for enzymes
involved in the synthesis of neurotransmitters (Hu & Connor, 1996), but excess iron can
be toxic due to its ability to catalyze the formation of ROS (Wallander et al., 2006). Brain
iron levels vary widely depending on the region, with iron in the basal ganglia reaching
concentrations equal to that in the liver, but generally show a high rate of increase with
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age soon after birth which then levels off in adulthood to a slow rate that remains
relatively constant for the remainder of life (Tarohda et ah, 2004; Connor et ah, 2001;
Hallgren & Sourander, 1958).
For iron to reach cells in the brain, it must first be transported across the bloodbrain barrier, after which the uptake and storage of iron into individual cells is regulated
by the same proteins involved in iron regulation in other cells of the body (Hu & Connor,
1996). Since the brain is relatively susceptible to oxidative stress, stringent regulation of
iron homeostasis is critical (Pinero et ah, 2000a). The key players in the regulation of
cellular iron metabolism are the iron regulatory proteins (IRPs), IRP1 and IRP2, which
regulate the translation of proteins involved in iron transport, storage and utilization in
response to changing levels of “free” or loosely bound iron in the cytosol (Wallander et
ah, 2006). IRP2 is less abundant than IRP1 in most cells and shows a more restricted
tissue distribution, with the strongest expression in the brain and intestines. However, as
only IRP2 is responsive to fluctuations in iron concentrations under physiological oxygen
tensions, it is thought to dominate iron regulation in vivo (Meyron-Holtz et ah, 2004b).
IRPs are cytoplasmic RNA binding proteins that bind to hairpin structures called iron
responsive elements (IREs) found on the 5’- or 3’- UTRs of target mRNAs to block
translation or stabilize the message, respectively. When intracellular iron levels are low,
both IRPs are able to bind IREs, but when iron is abundant, IRP1 is inactivated while
IRP2 is degraded. For instance, in a state of iron deficiency, IRPs bind to the single IRE
located on the 5’- UTR of ferritin mRNA and inhibit its translation while in the same
condition IRPs bind to five IREs on the 3’- UTR of the mRNA for transferrin receptor,
stabilizing the mRNA and upregulating protein synthesis. The net result is an increased
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cellular uptake of iron and less sequestering of iron into ferritin. In the presence of excess
iron, IRP1 is inactivated while IRP2 is degraded, leading to an increased synthesis of
ferritin and reduced production of transferrin receptor (Wallander et ah, 2006; Hentze et
ah, 2004).
Iron homeostasis is also affected by factors such as cytokines and nitric oxide
(NO) (Hentze et ah, 2004; Torti & Torti, 2002). Cytokines, including IL-la, IL-1|3, IL-6
and TNF-a, influence intracellular iron by modulating the expression of transferrin
receptor and ferritin (Rogers, 1996; Miller et ah, 1991; Tsuji et ah, 1991). Stimulation of
macrophages with interferon-y (IFN- y) induces NO synthesis and activates IRP/IRE
binding (Weiss et ah, 1993). Additionally, IL-2 elevates the levels of transferrin receptor
mRNA by stimulating IRP binding activity (Seiser et ah, 1993) while IL-1(3 increases the
intracellular labile iron pool and translation of ferritin mRNA in human astrocytoma cells
(Pinero et ah, 2000b).

Iron Dysregulation in Neurodegeneration
Increasing evidence implicates a dysregulation of brain metals, especially iron
and copper, early in the pathogenesis of AD (Todorich & Connor, 2004; Perry et ah,
2002; Smith et ah, 1997). Polymorphisms in the hemochromatosis gene that can promote
excess iron accumulation have been shown to lower the age of AD onset by
approximately five years (Rogers & Lahiri, 2004; Venti et ah, 2004; Sampietro et ah,
2001). The IRE present on the 5’- UTR of the APP mRNA is capable of mediating
increased translation of APP by iron through its interaction with IRPs (Rogers et ah,
2002). Furthermore, elevated levels of redox-active iron and copper capable of generating
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ROS have been found associated with or in the vicinity of amyloid plaques and NFTs in
the brains of AD patients (Lovell et ah, 1998; Smith et ah, 1997) and of mouse models of
AD pathology/amyloidosis including the APP and APP/PS1 transgenic mice, using both
MRI and histological methods (El Tannir El Tayara et ah, 2006; Falangola et ah, 2005;
Vanhoutte et ah, 2005). Trace metals such as iron and copper have been found to be
responsible for promoting the aggregation of Ap into neurotoxic oligomers, previously
thought to occur spontaneously (Cuajungco et ah, 2005; Huang et ah, 2004a; Mantyh et
ah, 1993). Furthermore, iron and copper have a high affinity for and interact with A(3 to
generate ROS that mediate its neurotoxicity, shown to be attenuated with iron removal
from amyloid fibrils by chelation and restored by incubation with redox-active iron
(Rottkamp et ah, 2001; Huang et ah, 1999). Thus, these findings demonstrated that the
toxicity of A(3 in cultures is dependent on its direct interaction with iron (Rottkamp et ah,
2001).
Since IRPs, and especially IRP2, is at the center of iron homeostasis, it is not
surprising that alterations in IRP function and localization have also been reported in AD
brain. These include findings of more stable IRE/IRP binding in a subset of AD patients
compared to controls (Pinero et ah, 2000a), and a colocalization of IRP2 but not IRP1
with a proportion of intracellular NFTs in AD hippocampus although no differences in
total protein was found when compared to controls (Smith et ah, 1998). However, no
study has yet examined IRP2 expression at different stages of the disease, and little is
known about the relative distribution of the different pools of iron in AD brain, especially
of loosely bound iron, the level of which is thought to be sensed by IRPs in their
regulation of iron homeostasis proteins.
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Recently, mice with a targeted deletion of IRP2 but not IRP1 were reported to
develop adult-onset neurodegeneration, with axonopathy, vacuolization, ubiquitin
inclusions and microglial activation in affected regions of the brain (Meyron-Holtz et al.,
2004a; Smith et ah, 2004; Grabill et ah, 2003; LaVaute et ah, 2001). Symptoms of
cognitive impairment became apparent beginning at approximately six months and
worsened progressively with age (LaVaute et ah, 2001). IRP1+/-IRP2-/- mice developed
a more severe form of neurodegeneration compared to IRP2-/- mice (Smith et ah, 2004),
and IRP1-/-IRP2-/- mice did not survive past the blastocyst stage (Smith et ah, 2006).
IRP2-/- mice accumulated ferric iron and overexpressed ferritin in white matter tracts of
the striatum and thalamus months before symptoms became apparent. Moreover, the iron
accumulation and neurodegeneration colocalized (Smith et ah, 2004; LaVaute et ah,
2001). Following the development of this first mouse model of IRP2 deficiency made by
a constitutive inactivation of IRP2 by LaVaute et ah (2001), an independent group
generated a separate line of IRP2-/- mice with a conditional inactivation of IRP2, for
which a differing phenotype, with less neurodegenerative symptoms, was reported (Galy
et ah, 2006). Whether the symptomatic inconsistencies between the two IRP2-/- mouse
lines arise from varying genetic backgrounds or knockout methods is unclear (Wallander
et ah, 2006).

Neuroinflammation in AD
It is well established that inflammation is involved in the pathogenesis of AD but
whether it plays a role in the initiation and progression of the disease or is a secondary
result of neuronal damage is unknown. However, emerging evidence suggest that
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inflammation is an early event in the disease process and can be observed both in the
CNS and periphery (Griffin, 2006; Neuroinflammation Working Group, 2000).
Inflammatory cytokines, C-reactive protein, activated microglia and immigration of
certain T lymphocytes are found in association with AD neuropathology, including
amyloid plaques and NFTs (McGeer et ah, 1989; Griffin et ah, 1995; Singh, 1997;
Neuroinflammation Working Group, 2000). Furthermore, polymorphisms in genes
encoding inflammatory cytokines such as IL-la, IL-lp and TNF-a that favor their
production have been suggested to enhance the risk for AD (McGeer & McGeer, 2003;
McCusker et al., 2001; Du et al., 2000; Licastro et al., 2000). IL-6, a cytokine released by
neurons in response to injury (Murphy et al., 1995) and also by astrocytes and microglia,
has been found associated with amyloid plaques (Hull et al., 1996). IL-1 and S100p,
produced by astrocytes and known to stimulate neurite growth and astrocyte proliferation,
have been demonstrated to increase neuronal APP expression (Li et al., 1998; Forloni et
al., 1992). IL-1 has also been shown to induce the upregulation of both SlOOp and APP in
vitro and in vivo (Rogers et al., 1999; Sheng et al., 1996).
Additionally, IL-1 and S100{3 have been implicated in driving amyloid plaque
evolution. Although strict classifications are artificial, researchers have attempted to
roughly divide plaques into several types based on the stage of disease progression
(Griffin et al., 1995). Plaques are thought to start as simple, diffuse nonneuritic deposits
of Ap with the least dense deposition of A(3 and no dystrophic neuritis. The next stage
consists of dense-core neuritic plaques which contain diffuse and compact amyloid, and
the most developed “burned out” plaque, dense-core nonneuritic plaques, is formed from
compact Ap without the presence of dystrophic neurites. Both IL-1 and S100p expression

14

were found to be greatest in diffuse neuritic plaques. Dense-core neuritic plaques had the
next highest expression while hardly any IL-1 or SI00(3 expression was seen in densecore nonneuritic plaques (Mrak et ah, 1996; Griffin et ah, 1995; Van Eldik & Griffin,
1994). SI00(3 was also found to be elevated in the cerebrospinal fluid (CSF) of mildmoderate AD subjects but not in elderly controls or severe AD (Peskind et al., 2001).
Furthermore, almost all individuals with Down’s syndrome (DS) develop AD in middle
age, allowing an opportunity to examine the development of AD even before A(3 deposits
become apparent, usually after adolescence (Griffin et al., 1989). IL-1 and S100p
overexpression has been shown to occur decades before amyloid plaques and NFTs
develop in DS (Griffin, 2006; Royston et al., 1999), with overexpression of IL-1 even
found in prenatal and postnatal DS brains (Griffin et al., 1989).

Peripheral Inflammation
The difficulty of assessing inflammation in the brain in living AD patients has
lead focus to the examination of the peripheral immune response, especially leukocyte
distribution and cytokine production, although the data have been inconsistent. It has
been shown that the proportion of CD4+ lymphocytes is elevated (Lombardi et al., 1999)
while CD8+ lymphocytes are decreased (Lombardi et al., 1999; Hu et al., 1995; Pirttila et
al., 1992) in AD patients relative to healthy aged-matched controls. Decreased T
lymphocytes (CD3+) and B cells (CD 19+) have also been reported in AD (RichartzSalzburger et al., 2007; Speciale et al., 2006). In addition, a decrease in the proliferative
ability of peripheral blood mononuclear cells (PBMCs) in AD patients has been
demonstrated (Lombardi et al., 1999). However, other reports indicate no differences in
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either CD4+/CD8+ cell ratios (Ikeda et ah, 1991), total lymphocytes (Dysken et ah,
1992) or the percentage of T lymphocytes (Lombardi et ah, 1999) between AD and
controls. Differences in methodology or heterogeneity in the selection of patients with
respect to the severity of dementia may partly account for these differences as Shalit et al.
(1995) found a significant increase in CD4+ cells and a decrease in lymphocyte
proliferation in moderately severe, but not mild AD patients.
A recent report demonstrated decreased levels of IL-6 in the serum and TNF-a in
the CSF as well as production of the proinflammatory cytokines IL-6, IL-12, IFN-y and
TNF-a in whole blood cell cultures of AD patients compared to age-matched controls,
suggesting an attenuated immune response (Richartz et al., 2005a; Richartz et al., 2005b).
Production of IL-10 was also significantly decreased in AD patients when PMBCs were
stimulated with Ap40 (Speciale et al., 2006). However, other studies have shown elevated
levels of TNF-a, IL-lp, IL-6 and IL-10 (Lombardi et al., 1999) and higher pro- to anti
inflammatory cytokine ratios, both IL-lp/IL-10 and IL-6/IL-10, in lipopolysaccharide
(LPS) stimulated whole blood cultures from AD patients compared to controls,
suggesting a proinflammatory phenotype in AD (Remarque et al., 2001). These
seemingly contradictory reports may also be partly explained by changes specific to
certain disease stages as demonstrated by a study that found decreased IL-ip, IL-6 and
TNF-a release from LPS stimulated peripheral blood from severe AD patients but no
difference between mild and moderate AD patients and controls (Sala et al., 2003).
Moreover, epidemiological studies have found that use of non-steroidal anti
inflammatory drugs (NSAIDs) may help delay or prevent the onset of AD (Szekely et al.,
2004; in f Veld et al., 2001). However, clinical trials that have examined NSAID
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treatment on AD patients to slow down disease progression do not support their
effectiveness (Reines et al., 2004; Aisen et al.5 2003). The majority of epidemiological
studies on NSAIDs have investigated the likely incidence of AD prior to the onset of
clinical symptoms, and this discrepancy has given rise to the hypothesis that NSAIDs are
optimally effective as a preventive therapy to delay the onset and even the progression of
AD before clinical symptoms appear or in individuals at high risk for AD such as those
with mild cognitive impairment (MCI) (Pasinetti, 2005). Many therapeutic studies target
those with advanced stages of AD at which point inflammatory processes may have
already done the damage.

Mild Cognitive Impairment
MCI describes a pre-clinical stage of AD, applied to a transitional state between
normal aging and early AD. The progression rate from MCI to AD range between 1015% per year, with an 80% conversion after six years of follow up, compared to 1-2% per
year in the general population. This group, at increased risk for AD, is gaining attention
in the search for biomarkers and clinical trials to prevent or delay cognitive decline
(Blasko et al., 2006; Thai et al., 2005; Petersen, 2004). Unlike studies on AD patients, the
data on MCI subjects have been relatively consistent in demonstrating an increased
inflammatory response. For instance, interferon-y-inducible protein 10 (IP-10) in CSF
and monocyte chemotactic protein-1, a beta chemokine, in serum was shown to be
upregulated in MCI and mild AD but not in severe AD patients. Moreover, IP-10
appeared to decrease with disease progression (Galimberti et al., 2006a; Galimberti et al.,
2006b). Additionally, both MCI and AD patients who had progressed from MCI had
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higher TNF-a (proinflammatory cytokine) to TGF-p (anti-inflammatory cytokine) ratios
in CSF when compared to controls, indicating a higher proinflammatory state in patients
at risk for AD (Tarkowski et ah, 2003). Furthermore, Migliore et al. (2005) demonstrated
increased DNA damage in peripheral leukocytes of MCI and AD patients relative to
controls, suggesting the possibility that inflammation and alterations in peripheral blood
cells may be an early event in AD or even precede the clinical development of the
disease. Thus, the controversial data regarding a heightened versus a decreased
inflammatory response in AD may derive from an initial increase in the early stages of
the disease, which can be seen in MCI subjects, that attenuates over time. However, no
study has examined the relative distribution of peripheral blood cell subpopulations or
their ability to produce cytokines in subjects with MCI even though a significant
proportion of these patients eventually transition into mild AD.

Purpose of Study
Despite the accumulating evidence for alterations in iron homeostasis and
inflammation in AD, their roles in disease development are currently unclear. The
purpose of these experiments was to characterize the disturbance in iron metabolism and
immune responses prior to or at the beginning stages of neurodegeneration or cognitive
decline based on our hypothesis that they are early events in the pathogenesis of AD. We
measured regional levels of loosely bound, non-heme, and total iron and copper in the
brains of young and aged IRP2-/- mice before and after the onset of neurodegeneration.
Additionally, regional metal concentrations were determined in aged IRP1+/-IRP2-/mice which exhibit a more severe form of neurodegeneration compared to IRP2-/- mice
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(Smith et al., 2004). We have used the IRP2-/- mice as a model for neurodegeneration
instead of an AD mice model as iron dysregulation dependent neurodegeneration was the
focus of this study and also because no single mouse model is available that replicates all
aspects of the disease, especially the critical neural and synaptic degeneration that leads
to the clinical symptoms of AD (McGowan et al., 2006). Similar experiments, as well as
immunohistochemical studies to evaluate IRP2 expression, were done on vulnerable
regions of AD brain at different stages of the disease to corroborate and confirm the
relevance of the findings in mice as the examination of human brains prior to the
appearance of clinical symptoms of AD is not feasible.
In the second part of the study, we determined if a tendency toward inflammation
could be seen prior to clinical AD by examining the distribution and cytokine production
of immune cells in MCI subjects. Additionally, expression of the hallmark proteins of
AD, APP and Af3, were evaluated in lymphocytes and monocytes from MCI subjects
compared to elderly controls. Because neuronal loss is currently irreversible, our study is
important for elucidating processes that occur in the initiating stages of the disease for
early diagnosis and therapeutic intervention, critical in delaying the progression of AD.
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Abstract
Iron is a trace metal essential for normal brain development but toxic in excess as
it is capable of generating highly reactive radicals that damage cells and tissue. Iron is
stringently regulated by the iron regulatory proteins, IRP1 and IRP2, which regulate
proteins involved in iron homeostasis at the posttranscriptional level. In this study, 12
distinct regions were microdissected from the mouse brain and regional changes in the
levels of loosely bound and non-heme iron that occur with development were measured.
We examined 6, 12, and 24 week old wildtype C57BL/6 mice and mice with a targeted
deletion of iron regulatory protein 2 (IRP2-/-) that have been reported to develop
neurodegenerative symptoms in adulthood. In wildtype mice, levels of loosely bound iron
decreased while non-heme iron increased with development. In contrast, an increase in
loosely bound iron with age was seen in IRP2-/- mice, stemming from lower levels at the
youngest age compared to wildtype. Furthermore, the increase in non-heme iron was
more pronounced in the IRP2-/- mice. These results have implications for understanding
the increase in regional brain iron that is associated with normal aging and is postulated
to be exacerbated in neurodegenerative disorders.
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1. Introduction
Iron is essential for many cellular functions but must be stringently regulated as it
is one of the most abundant redox-active metals, capable of catalyzing the production of
reactive oxygen species (ROS). In fact, most ROS are generated from the reaction
between molecular oxygen and Fe (II) or Cu (I) (Perry et ah, 2002; Bamham et ah, 2004).
It is well known that brain iron is important in development and normal neurologic
function (Beard et ah, 2002). Neurons and glial cells require iron for electron transport,
NADPH reductase activity, myelination of axons, and as a cofactor for enzymes involved
in the synthesis of neurotransmitters (Hu and Connor, 1996). However, while iron
deficiency impairs cell growth in culture, iron overload can cause cellular damage. Thus,
the maintenance of iron homeostasis is critical for the cell (Hentze et ah, 2004; Rouault,
2006; Wallander et ah, 2006).
Approximately two thirds of total iron in the human body is found in the
hemoglobin of red blood cells, which functions in oxygen transport, and 10% is in
myoglobin (Halliwell and Gutteridge, 1984). Other heme iron containing proteins include
cytochrome P450, a, b, and c in the electron transport chain. Non-heme iron consists of
iron tightly bound to proteins such as the iron transport proteins transferrin and
lactoferrin and enzymes such as cytochrome oxidase, prolylhydroxylase, and tyrosine
hydroxylase. The remaining non-heme iron is found in the intracellular storage protein
ferritin and hemosiderin (Halliwell and Gutteridge, 1984; Gutteridge, 1992; Levenson
and Tassabehji, 2004). Ferritin is the main iron storage protein in the brain, binding about
one third of total brain iron (Bradbury, 1997; Koeppen, 2003), and iron stored in ferritin
is not catalytically active under normal conditions (Kagan et al., 2001). Loosely bound
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iron is a labile, chelatable pool of non-heme iron that mediates the transfer of iron from
ferritin storage sites to where it is needed for enzymatic and biosynthetic activity. It
consists of iron attached to phosphate esters, carbohydrates, organic acids, DNA, and
membrane lipids (Gutteridge, 1992; Kala et ah, 1996) and is thought to be responsible for
catalyzing the formation of ROS, such as the highly reactive hydroxyl radical from
hydrogen peroxide, a normal metabolic byproduct, via the Fenton reaction (Gutteridge et
ah, 1981; Halliwell and Gutteridge, 1984; Jacobs, 1977). Therefore, dysregulation of
loosely bound iron would lead to increased oxidative damage which is implicated in
aging and neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
(Doraiswamy and Finefrock, 2004).
An imbalance in brain iron has been associated with normal aging and
neurodegenerative disorders (Smith et ah, 1997; Sayre et ah, 1999; Perry et ah, 2002;
Huang et ah, 2004; Todorich and Connor, 2004) and perturbation of iron homeostasis
proteins can lead to neuropathology in mouse models (LaVaute et ah, 2001; Jeong and
David, 2006). Studies on rat and mouse brain have shown that iron increases with
development (Roskams and Connor, 1994; Maynard et ah, 2002; Tarohda et ah, 2004),
and brain non-heme iron increases with normal aging in humans (Hallgren and
Sourander, 1958). However, little is known about the regional distribution of loosely
bound iron in development. An understanding of the distribution of loosely bound iron is
important as this pool of iron is thought to be responsible for catalyzing the reactive
radicals that damage DNA and membrane lipids in the cell (Hentze et ah, 2004).
To study changes in regional brain levels of loosely bound and non-heme iron
with development, we measured their concentrations in 12 distinct brain regions of two
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substrains of C57BL/6 mice, C57BL/6NTac from Taconic Laboratories and C57BL/6J
from the Jackson Laboratory, at the ages of 6, 12, and 24 weeks. Brains were fixed with
focused microwave irradiation (MWR) which preserves labile brain metabolites
(Schneider et ah, 1981) and was shown to be an optimal method of preserving loosely
bound iron in this study. We also measured iron concentrations in transgenic mice with a
targeted deletion of iron regulatory protein 2 (IRP2) generated by LaVaute et al. (2001).
These mice are reported to accumulate iron in certain brain regions and exhibit
neurodegenerative symptoms that worsen with age, and disturbances in the loosely bound
and non-heme iron pools should be detected prior to the onset of neurodegeneration.
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Figure 2. Loosely bound iron (presented as mean ± SD) in the brains of C57BL/6 mice
sacrificed by cardiac perfusion, cervical dislocation, decapitation, drug overdose, and
MWR (n = 5 for each method).
< 0.001 MWR vs all other methods.
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2. Results
2.1. Loosely bound iron in wildtype mice
In the brains of wildtype mice, loosely bound iron levels either remained constant
or decreased with development in a region specific manner while whole brain loosely
bound iron concentrations did not change with age (Table 1). Slight regional differences
were seen between the two substrains of C57BL/6 mice even though the general trend
was similar. In BL/6NTac mice, loosely bound iron decreased by 26% in the ventral
striatum and 29% in the thalamus between 6 weeks and 12 weeks of age. Furthermore, in
comparison with the youngest group (6 weeks), loosely bound iron levels significantly
decreased at 12 and 24 weeks in the dorsal striatum and at 24 weeks in the septum.
However, in BL/6J mice, a significant decrease in loosely bound iron was only observed
at 24 weeks in the frontal cortex, cerebellum and hypothalamus compared to the youngest
group.
Comparison across substrains showed that loosely bound iron levels were
decreased in BL/6J mice compared to BL/6NTac mice in the parietal cortex, dorsal
striatum, thalamus and brainstem at the youngest age (Table 4). This is reflected in lower
levels of whole brain loosely bound iron at 6 weeks of age. However, all of these
differences disappear with increasing age except for reduced loosely bound iron levels in
the olfactory bulb and hypothalamus of BL/6J mice at 12 and 24 weeks, respectively.

2.2. Non-heme iron in wildtype mice
In contrast to loosely bound iron, non-heme iron regionally increased with
development in wildtype mice (Table 2). This is reflected in a significant increase in
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whole brain non-heme iron in both wildtype substrains. Non-heme iron significantly
increased in the olfactory bulb, frontal cortex, cerebellum and ventral striatum of
BL/6NTac and BL/6J mice with age. The BL/6NTac substrain demonstrated additional
increases in the septum, hypothalamus and entorhinal cortex while increases in the
parietal cortex and thalamus were restricted to BL6/J mice. Non-heme iron levels
remained constant in the brainstem in both groups. There were no differences in non
heme iron between BL6/NTac and BL6/J mice at any of the ages examined, except for
the olfactory bulb which, as with loosely bound iron, showed reduced levels in BL6/J
mice at 12 weeks only.

2.3. Loosely bound iron in IRP2-/- mice
Additionally, we measured iron levels in the brains of transgenic mice with a
targeted deletion of IRP2 generated by LaVaute et al. (2001). Intracellular iron is tightly
regulated by the iron regulatory proteins, IRP1 and IRP2, which regulate the translation
of proteins involved in iron homeostasis, such as the transferrin receptor and ferritin, in
response to cytosolic “free” iron concentrations (Glickstein et al., 2005; Wallander et al.,
2006). IRP2-/- mice have been reported to exhibit misregulation of iron in the brain,
accumulate increased ferritin iron, and develop neurodegenerative symptoms in
adulthood between 24 to 48 weeks of age (LaVaute et al., 2001; Grabill et al., 2003;
Smith et al., 2004). Thus, mice were examined at 6, 12, and 24 weeks of age to determine
if changes in iron levels could be observed before the appearance of symptoms.
Similar to normal mice, loosely bound iron remained constant with development
in most brain regions of IRP2-/- mice (Table 1). However, in contrast to the two non-
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transgenic substrains, loosely bound iron increased significantly in the ventral striatum by
39% between 6 and 12 weeks and in the thalamus by 32% between 6 and 24 weeks
(Table 1). Furthermore, there was a significant increase in loosely bound iron in the
whole brain of IRP2-/- mice with age.
However, comparison of IRP2-/- mice with both non-transgenic substrains
demonstrated significantly reduced levels of loosely bound iron in the knockout mice at 6
weeks of age (Table 4). This is seen in whole brain and ventral striatum compared with
BL6/J mice and in whole brain and every region except the hippocampus and septum
compared with BL6/NTac mice. However, this difference rapidly disappears with age,
with reduced levels of loosely bound iron only in the cerebellum compared with BL6/J
mice and in the olfactory bulb compared with BL6/NTac mice at 12 weeks. Moreover,
loosely bound iron levels are similar between knockouts and non-transgenics at 24 weeks
of age, except for higher levels in the ventral striatum in IRP2-/- mice compared to BL6/J
mice. This reflects the regional increase in loosely bound iron seen in IRP2-/- mice with
age.

2.4. Non-heme iron in IRP2-/- mice
The general increase of non-heme iron with age in normal mice was exacerbated
in the parietal cortex, septum and thalamus of IRP2-/- mice (Table 2). In the parietal
cortex, BL/6NTac mice showed no change in non-heme iron and BL/6J mice displayed
an 18% increase between 6 and 12 weeks. However, in IRP2-/- mice, non-heme iron
levels increased by 17% between 6 and 12 weeks and further by 26% between 12 and 24
weeks. In the thalamus there was again no change in non-heme iron in BL/6NTac mice
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and a 13% increase between 12 and 24 weeks in BL/6J mice. In IRP2-/- mice this
increase was elevated to 23% between 12 and 24 weeks. In the septum BL/6NTac mice
exhibited a 21% increase of non-heme iron between 6 and 24 weeks of age whereas
BL/6J mice did not show any change. In contrast, non-heme iron levels increased in
IRP2-/- septum by 19% between 6 and 12 weeks and further by 20% between 12 and 24
weeks of age. However, while BL/6NTac mice showed a significant increase in non
heme iron in the hypothalamus and entorhinal cortex, neither BL/6J nor IRP2-/- mice
exhibited any significant changes in these regions.
Similar to loosely bound iron, IRP2-/- mice showed reduced levels of non-heme
iron compared with the non-transgenics in whole brain and several of the regions
investigated at 6 weeks (Table 5). This reduction in non-heme iron disappears with age
and is abolished at 24 weeks compared to BL/6J mice, while it is still observed for the
cerebellum and hypothalamus in comparison with BL/6NTac mice. This may be due to
the exacerbated regional increase in non-heme iron levels seen in IRP2-/- mice with age.
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Table 1 Regional concentrations of loosely bound iron (presented as mean ± SD) with
development in two non-transgenic mouse lines, C57BL/6NTac and C57BL/6J, and
IRP2-/- mice at 6, 12, and 24 weeks. OB, olfactory bulb; FC, frontal cortex; PC, parietal
cortex; CB, cerebellum; HP, hippocampus; DS, dorsal striatum; VS, ventral striatum; SP,
septum; TH, thalamus; HY, hypothalamus; EC, entorhinal cortex, BS, brainstem. %A,
percentage difference in iron concentration between 6 wk and 12 wk or 12 wk and 24 wk.
ap < 0.05 vs 6 wk, hp < 0.01 vs 6 wk,cp < 0.05 vs 12 wk.
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Table 2 Regional concentrations of non-heme iron (presented as mean ± SD) with
development in two non-transgenic mouse lines, C57BL/6NTac and C57BL/6J, and
IRP2-/- mice at 6, 12, and 24 weeks. OB, olfactory bulb; FC, frontal cortex; PC, parietal
cortex; CB, cerebellum; HP, hippocampus; DS, dorsal striatum; VS, ventral striatum; SP,
septum; TH, thalamus; HY, hypothalamus; EC, entorhinal cortex, BS, brainstem. %A,
percentage difference in iron concentration between 6 wk and 12 wk or 12 wk and 24 wk.
ap < 0.05 vs 6 wk, bp < 0.01 vs 6 wk,cp < 0.001 vs 6 wk,dp < 0.05 vs 12 wk,e/? < 0.01
vs 12 wk.
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Table 3 Significant differences in levels of loosely bound iron between mouse strains
(C57BL/6J versus C57BL/6NTac; IRP2-/- versus C57BL/6NTac and C57BL/6J
respectively) at 6, 12, and 24 weeks. OB, olfactory bulb; FC, frontal cortex; PC, parietal
cortex; CB, cerebellum; HP, hippocampus; DS, dorsal striatum; VS, ventral striatum; SP,
septum; TH, thalamus; HY, hypothalamus; EC, entorhinal cortex, BS, brainstem. Light
green (+++) marks significantly increased iron and light red (—) marks significantly
decreased iron compared to C57BL/6NTac or C57BL/6J. p < 0.05 was considered
significant.
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Table 4 Significant differences in levels of non-heme iron between mouse strains
(C57BL/6J versus C57BL/6NTac; IRP2-/- versus C57BL/6NTac and C57BL/6J
respectively) at 6, 12, and 24 weeks. OB, olfactory bulb; FC, frontal cortex; PC, parietal
cortex; CB, cerebellum; HP, hippocampus; DS, dorsal striatum; VS, ventral striatum; SP,
septum; TH, thalamus; HY, hypothalamus; EC, entorhinal cortex, BS, brainstem. Light
green (+++) marks significantly increased iron and light red (—) marks significantly
decreased iron compared to C57BL/6NTac or C57BL/6J. p < 0.05 was considered
significant.
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3. Discussion
This study examined regional levels of loosely bound and non-heme iron in the
brains of two substrains of wildtype C57BL/6 mice and IRP2-/- mice at 6, 12, and 24
weeks of age. Although the general trends in brain iron levels during development
between the substrains of inbred wildtype mice were very similar, namely a reduction in
loosely bound iron and an increase in non-heme iron, regional differences were found.
This could reflect the minor genetic differences between true substrains due to genetic
drift in the form of different point mutations over many generations described between
these two wildtype substrains (Silver, 1995; Bothe et al., 2004).
We found that loosely bound iron levels either remained constant or decreased
with age in wildtype mice. It was lowest in the frontal cortex and brainstem and highest
in the septum and dorsal striatum. This is consistent with Nelson et al. (2000) who found
the highest levels of loosely bound iron in the caudate nucleus of rats. The regions found
to contain high levels of loosely bound iron also correlate with regions reported as having
little or no IRP2 staining in the brain (Leibold et al., 2001). They suggest that the little
immunoreactivity for IRP2 in regions reported to be high in iron may be due to the more
rapid turnover of IRP2. In contrast to loosely bound iron, we observed a general regional
and age-dependent increase in non-heme iron in both C57BL/6 substrains in agreement
with reports of increasing levels of iron with development in rats (Roskams and Connor,
1994; Tarohda et a., 2004). Non-heme iron levels increased with age in the majority of
regions which is reflected in the increase in non-heme iron in whole brain. The highest
concentrations of non-heme iron were seen in the olfactory bulb, followed by the ventral
striatum and septum in both substrains.

40

Whereas loosely bound iron levels either remained constant or decreased with age
in wildtype mice, they increased in the ventral striatum, thalamus and whole brain in
IRP2-/- mice. This increase in loosely bound iron seems to arise from low levels of
loosely bound iron at 6 weeks compared to the wildtype mice as concentrations are
relatively similar again at 24 weeks across strains. This is in support of previous findings
by LaVaute et al. (2001), who describe axonal degeneration following ferric iron and
ferritin accumulation in white matter tracts of the striatum and thalamus and a decrease in
transferrin receptor 1 in IRP2-/- mice concomitant with a progressive neurodegenerative
movement disorder. They postulate that this neurodegeneration may be due to iron
deficiency from increased iron sequestration into overexpressed ferritin. Furthermore,
while

reporting

a milder clinical phenotype without pathological

signs

of

neurodegeneration in a different mouse model of IRP2 deficiency, Galy et al. (2006) also
show decreased transferrin receptor 1 and increased ferritin expression in the brain. As it
is generally accepted that there is an association between iron deficiency during early age
and poor cognitive and motor development (Grantham-McGregor, et al., 2001) the
observed deficiency in loosely bound iron in younger mice could set the stage for the
described clinical symptoms in both strains of IRP2-/- mice.
The increase in non-heme iron seen in wildtype mice with age was exacerbated in
some regions in IRP2-/- mice. Furthermore, this exacerbated increase appears to originate
from lower levels of non-heme iron at a younger age in IRP2-/- mice as levels are
comparable by 24 weeks of age. Therefore, this is not in contrast to findings by Galy et
al. (2006) who report no difference in non-heme iron levels in whole brain and
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cerebellum in their IRP2-/- mice at approximately twice the age of mice used in this
study.
In this study, significant differences, although not dramatic, in iron levels and
distribution were observed between two substrains of C57BL/6 and IRP2-/- mice with
age. These results suggest that the redundancy in function in IRP1 serves to partly
compensate for the absence of a critical protein such as IRP2, which is consistent with
mice lacking both IRP1 and IRP2 being embryonic lethal (Smith et al., 2006). We
examined younger IRP2-/- mice to determine if changes in iron metabolism could be
observed prior to the development of neurodegenerative symptoms and our findings are
consistent with the report that IRP2-/- mice develop normally and symptoms are not seen
until later in life (LaVaute et al., 2001). Little is known about the role of IRP2 on the
regional homeostasis of the different pools of iron in the mouse brain. We were able to
show that normal distribution of iron with development is at least in part dependent on
functional IRP2.
We have further shown that loosely bound iron is regionally decreased in normal
aging. This may be due to the higher utilization of iron during growth which gradually
slows with further maturation. In contrast to non-transgenic mice, IRP2-/- mice
demonstrated an increase in loosely bound and non-heme iron with age in several brain
regions which may be attributed to lower levels of iron at younger ages. These changes
could indicate early alterations in iron metabolism that may possibly lead to neuronal
dysfunction later in life. The results of this study have implications in elucidating the role
of iron in normal neurological maturation and neurodegeneration.
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4. Experimental Procedure
4.1. Mice
Transgenic mice with a targeted deletion of IRP2 (IRP2-/-) were bred at Taconic
from the IRP2-/- strain generated at the NIH (LaVaute et ah, 2001 - kindly provided by
TA Rouault) and have a mixed genetic background of C57BL/6J and B129S4/SVJae
mice in undefined proportions. As non-transgenic littermates were not available, we used
C57BL/6 mice from Jackson Laboratories (BL/6J, Bar Harbor, ME). To address the
variation in iron metabolism between substrains of the inbred C57BL/6 strain we
included

C57BL/6

mice

from

Taconic

Laboratories,

BL/6NTac

(BL/6NTac,

Germantown, NY). To our knowledge, variations in iron metabolism between different
inbred mouse strains have been investigated, but not between substrains of inbred strains.
Animals were bred at the respective company and then shipped to our local animal care
facility where they were maintained until use. All mice were housed and fed laboratory
chow and tap water ad libitum according to standard animal care procedures. The iron
content of chow at Taconic, Jackson Laboratories and our local animal care facility are
206, 345 and 345 mg/kg of food, respectively. Experimental protocols were approved by
the Institutional Animal Care and Use Committee of Loma Linda University in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Mice were analyzed at 6, 12, and 24 weeks, and all mice were male
to eliminate effects of gender.
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4.2. Preparation of brain tissue
Mice were anesthetized with Nembutal and the brains fixed with focused
microwave irradiation (MWR) for Is at 5 kW using the Muromachi Microwave Fixation
System, Model TMW-6402C (Tokyo, Japan). Fixing brains with MWR preserves labile
neurochemical compounds (Schneider et ah, 1981). Comparison with the methods of
cardiac perfusion, cervical dislocation, decapitation, and drug overdose showed that
MWR was best able to preserve brain loosely bound iron (Figure 2). After fixation, brains
were rapidly dissected according to a novel microdissection protocol developed in our
laboratory that allowed us to dissect 12 regions each from the right and left hemispheres
including: olfactory bulb (OB), frontal cortex (FC), parietal cortex (PC), cerebellum
(CB), hippocampus (HP), dorsal striatum (DS), ventral striatum (VS), septum (SP),
thalamus (TM), hypothalamus (HY), entorhinal cortex (EC), and brainstem (BS). Each
region was identified according to the mouse brain atlas of Paxinos and Franklin (2000).
Regions were weighed and processed immediately for the extraction of loosely bound
and non-heme iron.

4.3. Iron extraction and analysis
We extracted loosely bound and non-heme iron according to the method of
Nelson et al. (2000) with slight modifications. To minimize trace metal contamination,
polypropylene mortars and pestles (Kontes, Vineland, NJ) were used instead of
glassware, and MilliQ water was used for all buffers. For loosely bound iron, tissues were
homogenized in 180 pi of 0.5 mM EDTA, centrifuged at 13,000 x g for 10 min, and 34
pL of 20% trichloroacetic acid (TCA) in 0.5 mM EDTA was added to 120 pL of the
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supernatant. Then samples were vortexed, centrifuged again at 13,000 xg for 10 min, and
the supernatant collected and stored at -20 °C. For non-heme iron, tissues were
homogenized in 360 pL of 6% TCA /0.5 mM EDTA and incubated at 90 °C for 30 min.
Then 0.7 ml of 0.5 mM EDTA was added, and samples were vortexed, centrifuged at
13,000 x g for 10 min and the supernatant collected and stored at -20 °C. Iron
concentrations were measured in duplicate by graphite furnace atomic absorption
spectrometry (GFAAS) with a SpectrAA 220Z (Varian, Victoria, Australia).

4.4. Statistical analysis
Data are presented as means ± SD. Statistical analysis was performed using one
way ANOVA for each brain region and corrected for multiple comparisons using the
Bonferroni post hoc test with SPSS 12.0.1 software. A p value of < 0.05 was chosen to
indicate significance.

Acknowledgements
We want to thank Dr. TA Rouault, Dr. RE Levine, Dr. EA Leibold, Dr. MW
Hentze and colleagues for suggestions on the manuscript. This work was supported by
the National Institute on Aging, NIH, AG20948.

References
Bamham, K.J., Masters, C.L., Bush, A.I., 2004. Neurodegenerative diseases and
oxidative stress. Nat Rev Drug Discov. 3, 205-214.
Beard, J.L., Erikson, K.M., Jones, B.C., 2002. Neurobehavioral analysis of
developmental iron deficiency in rats. Behav Brain Res. 134, 517-524

45

Bothe, G.W.M., Bolivar, V.J., Vedder, M.J., Geistfeld, J.G., 2004. Genetic and
behavioral differences among five inbred mouse strains commonly used in the
production of transgenic and knockout mice. Genes Brain Behav. 3, 149-157.
Bradbury, M.W., 1997. Transport of iron in the blood-brain-cerebrospinal fluid system. J
Neurochem. 69, 443-454.
Doraiswamy, P.M., Finefrock, A.E., 2004. Metals in our minds: therapeutic implications
for neurodegenerative disorders. Lancet Neurol. 3, 431-434.
Galy, B., Holter, S.M., Klopstock, T., Ferring, D., Becker, L., Kaden, S., Wurst, W.,
Grone, H.J., Hentze, M.W., 2006. Iron homeostasis in the brain: complete iron
regulatory protein 2 deficiency without symptomatic neurodegeneration in the
mouse. Nat Genet. 38, 967-969.
Glickstein, H., El, R.B., Shvartsman, M., Cabantchik, Z.I., 2005. Intracellular labile iron
pools as direct targets of iron chelators: a fluorescence study of chelator action in
living cells. Blood. 106, 3242-3250.
Grabill, C., Silva, A.C., Smith, S.S., Koretsky, A.P., Rouault, T.A., 2003. MRI detection
of ferritin iron overload and associated neuronal pathology in iron regulatory
protein-2 knockout mice. Brain Res. 971, 95-106.
Grantham-McGregor, S., Ani, C., 2001. A review of studies on the effect of iron
deficiency on cognitive development in children. J Nutr. 131, 649-666.
Gutteridge, J.M., 1992. Iron and oxygen radicals in brain. Ann Neurol. 32, SI6-21.
Gutteridge, J.M., Rowley, D.A., Halliwell, B., 1981. Superoxide-dependent formation of
hydroxyl radicals in the presence of iron salts. Detection of'free' iron in biological
systems by using bleomycin-dependent degradation of DNA. Biochem J. 199,
263-265.
Hallgren, B., Sourander, P., 1958. The effect of age on the non-haemin iron in the human
brain. J Neurochem. 3, 41-51.
Halliwell, B., Gutteridge, J.M., 1984. Oxygen toxicity, oxygen radicals, transition metals
and disease. Biochem J. 219, 1-14.
Hentze, M.W., Muckenthaler, M.U., Andrews, N.C., 2004. Balancing acts: molecular
control of mammalian iron metabolism. Cell. 117, 285-297.
Hu, J., Connor, J.R., 1996. Demonstration and characterization of the iron regulatory
protein in human brain. J Neurochem. 67, 838-844.

46

Huang, X., Moir, R.D., Tanzi, R.E., Bush, A.L, Rogers, J.T., 2004. Redox-active metals,
oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci. 1012,
153-163.
Jacobs, A., 1977. Low molecular weight intracellular iron transport compounds. Blood.
50, 433-439.
Jeong, S.Y., David, S., 2006. Age-related changes in iron homeostasis and cell death in
the cerebellum of ceruloplasmin-deficient mice. J Neurosci. 26, 9810-9819.
Kagan, V.E., Kozlov, A.V., Tyurina, Y.Y., Shvedova, A.A., Yalowich, J.C., 2001.
Antioxidant mechanisms of nitric oxide against iron-catalyzed oxidative stress in
cells. Antioxid Redox Signal. 3, 189-202.
Kala, S.V., Hasinoff, B.B., Richardson, J.S., 1996. Brain samples from Alzheimer's
patients have elevated levels of loosely bound iron. Int J Neurosci. 86, 263-269.
Koeppen, A.H., 2003. A brief history of brain iron research. J Neurol Sci. 207, 95-97.
LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Meyron-Holtz, E., Drake,
S.K., Miller, G., Abu-Asab, M., Tsokos, M., Switzer, R. 3rd., Grinberg, A., Love,
P., Tresser, N., Rouault, T.A., 2001. Targeted deletion of the gene encoding iron
regulatory protein-2 causes misregulation of iron metabolism and
neurodegenerative disease in mice. Nat Genet. 27, 209-214.
Leibold, E.A., Gahring, L.C., Rogers, S.W., 2001. Immunolocalization of iron regulatory
protein expression in the murine central nervous system. Histochem Cell Biol.
115,195-203.
Levenson, C.W., Tassabehji, N.M., 2004. Iron and ageing: an introduction to iron
regulatory mechanisms. Ageing Res Rev. 3, 251-263.
Maynard, C.J., Cappai, R., Volitakis, I., Cherny, R.A., White, A.R., Beyreuther, K.,
Masters, C.L., Bush, A.L, Li, Q.X., 2002. Overexpression of Alzheimer's disease
amyloid-beta opposes the age-dependent elevations of brain copper and iron. J
Biol Chem. 277, 44670-44676.
Nelson, S.R., Pazdemik, T.L., Samson, F.E., 2000. Measurement of loosely bound iron in
brain regions using redox cycling and salicylate. Cell Mol Biol (Noisy-le-grand).
46, 649-655.
Paxinos, G., Franklin, K.B.J., 2000, The Mouse Brain in Stereotaxic Coordinates, Ed. 2,
Academic Press, San Diego.

47

Perry, G., Sayre, L.M., Atwood, C.S., Castellani, R.J., Cash, A.D., Rottkamp, C.A.,
Smith, M.A., 2002. The role of iron and copper in the aetiology of
neurodegenerative disorders: therapeutic implications. CNS Drugs. 16, 339-352.
Roskams, A.J., Connor, J.R., 1994. Iron, transferrin, and ferritin in the rat brain during
development and aging. JNeurochem. 63, 709-716.
Rouault, T.A., 2006. The role of iron regulatory proteins in mammalian iron homeostasis
and disease. Nat Chem Biol. 2, 406-414.
Sayre, L.M., Perry, G., Smith, M.A., 1999. Redox metals and neurodegenerative disease.
Curr Opin Chem Biol. 3, 220-225.
Schneider, D.R., Felt, B.T., Goldman, H., 1981. Microwave radiation energy: a probe for
the neurobiologist. Life Sci. 29, 643-653.
Silver, L.M., 1995, Mouse Genetics; Concepts and Applications, Oxford University
Press, Oxford.
Smith, M.A., Harris, P.L., Sayre, L.M., Perry, G., 1997. Iron accumulation in Alzheimer
disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA.
94, 9866-9868.
Smith, S.R., Ghosh, M.C., Ollivierre-Wilson, H., Tong, W.H., Rouault, T.A., 2006.
Complete loss of iron regulatory proteins 1 and 2 prevents viability of murine
zygotes beyond the blastocyst stage of embryonic development. Blood Cells Mol
Dis. 36, 283-287.
Smith, S.R., Cooperman, S., Lavaute, T., Tresser, N., Ghosh, M., Meyron-Holtz, E.,
Land, W., Ollivierre, H., Jortner, B., Switzer, R. 3rd., Messing, A., Rouault, T.A.,
2004. Severity of neurodegeneration correlates with compromise of iron
metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci.
1012,65-83.
Tarohda, T., Yamamoto, M., Amamo, R., 2004. Regional distribution of manganese,
iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem.
380, 240-246.
Todorich, B.M., Connor, J.R., 2004. Redox metals in Alzheimer's disease. Ann N Y Acad
Sci. 1012, 171-178.
Wallander, M.L., Leibold, E.A., Eisenstein, R.S., 2006. Molecular control of vertebrate
iron homeostasis by iron regulatory proteins. Biochim Biophys Acta. 1763, 668689.

48

CHAPTER THREE
IRON, COPPER, AND IRON REGULATORY PROTEIN 2 IN PATIENTS WITH
ALZHEIMER’S DISEASE AND RELATED DEMENTIAS

Shino Magaki1, Ravi Raghavan2, Claudius Mueller3, Kerby C. Oberg4, Harry V. Vinters5,
and Wolff M. Kirsch6*

1. Graduate student who conducted the majority of the experiments and the writing
2. Neuropathologist who supervised the research and writing of the manuscript
3. Graduate student who contributed to some of the experiments
4. Member of graduate student’s dissertation committee who contributed to the
immunohistochemistry experiments
5. Member of graduate student’s dissertation committee who provided the brain tissue
specimens
6. Graduate student’s mentor and chair of the dissertation committee who directed the
research and supervised the writing of the manuscript and dissertation

Neurosci Lett, (in press)

49

TITLE: Iron, copper, and iron regulatory protein 2 in Alzheimer’s disease and related
dementias

AUTHORS: Shino Magaki1, Ravi Raghavan2, Claudius Mueller1, Kerby C. Oberg3, Harry
V. Vinters4, and Wolff M. Kirsch i*

AUTHOR AFFILIATIONS:
Center for Neurosurgery Research,2 Neuropathology Section, Department of Pathology,
department of Pathology and Human Anatomy, Loma Linda University, Loma Linda,
CA, USA
4Section of Neuropathology, Department of Neurology, University of California, Los
Angeles, CA, USA

CORRESPONDING AUTHOR:
Wolff M. Kirsch, M.D.
wkirsch@llu.edu
email:
909-558-7070
phone:
909-558-0472
FAX:
Loma Linda University
Address:
Coleman Pavilion
1175 Campus Street, Suite 11113
Loma Linda, California 92350
KEYWORDS: Alzheimer’s disease, dementia with Lewy bodies; loosely bound iron;
non-heme iron

50

Abstract
Accumulating evidence implicates a role for altered iron and copper metabolism
in the pathogenesis of neurodegenerative disorders such as Alzheimer’s disease (AD).
However, imbalances in the levels of the various forms of iron at different stages of AD
have not been examined. In this pilot study we extracted and measured the levels of
loosely bound, non-heme and total iron and copper in the frontal cortex and hippocampus
of patients with mild-moderate AD (n = 3), severe AD (n = 8) and dementia with Lewy
bodies (DLB, n = 6), using graphite furnace atomic absorption spectrometry (GFAAS).
Additionally, the expression of iron regulatory protein 2 (IRP2) was examined in relation
to the pathological hallmarks of AD and DLB, amyloid plaques, neurofibrillary tangles
(NFT), and Lewy bodies, by immunohistochemistry. We found significantly decreased
loosely bound iron in the hippocampal white matter of mild-moderate and severe AD
patients and a trend towards increased non-heme iron in the hippocampal gray matter of
severe AD patients. Furthermore, decreased levels of total copper were seen in severe AD
and DLB frontal cortex compared to controls, suggesting an imbalance in brain metal
levels in both AD and DLB. The decrease in loosely bound iron in mild-moderate AD
patients may be associated with myelin breakdown seen in the beginning stages of AD
and implicates that iron dysregulation is an early event in AD pathogenesis.
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Introduction
A dysregulation of brain metals, especially iron and copper, has been implicated
in the pathogenesis of Alzheimer’s disease (AD) [15,22,27]. Brain iron is important in
neural development and function, as neurons and glial cells require iron for electron
transport, myelination of axons, and as a cofactor for enzymes involved in the synthesis
of neurotransmitters [14]. However, while iron deficiency impairs cell growth, iron
overload can cause cellular damage. Thus, the maintenance of iron homeostasis is critical
for the cell. Intracellular iron is tightly regulated by the iron regulatory proteins, IRP1 and
IRP2, which post-transcriptionally regulate the expression of proteins involved in iron
homeostasis, such as the transferrin receptor and ferritin, in response to intracellular
“free” iron concentrations [30].
Redox-active iron and copper, capable of generating reactive oxygen species
(ROS), have been found associated with amyloid plaques and neurofibrillary tangles
(NFT), pathological hallmarks of AD [19,27]. These and other transition metals were also
demonstrated to mediate (3-amyloid aggregation and neurotoxicity [15,24]. Furthermore,
alterations in the localization of IRP2, but not IRP1, have been reported in AD [26].
However, little is known about the relative distribution of the different pools of iron,
copper, and IRP2 expression at different stages of the disease. To address this question,
we measured the levels of 1) loosely bound, non-heme, and total iron, 2) copper, and 3)
examined IRP2 expression in the brains of patients with mild-moderate AD and severe
AD. In addition, we evaluated cases of dementia with Lewy bodies (DLB) to determine if
changes in iron levels and IRP2 expression are specific to AD or involved in both AD
and DLB.
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Materials and Methods
Postmortem tissue samples from the frontal cortex and hippocampus of nondemented elderly controls (n = 6, mean age = 72 ± 11 (SD), range = 56 to 86 years, M/F
= 4/2, postmortem interval (PMI) = 21 ±7), clinically and histopathologically confirmed
cases of mild-moderate AD (n = 3, mean age = 83 ± 10, range = 73 to 92 years, M/F =
1/2, PMI = 11 ± 11), severe AD (n = 8, mean age = 78 ± 12, range = 59 to 91 years, M/F
= 2/6, PMI = 21 ±6), using the CERAD/NIA and Braak/Braak staging criteria, and DLB
(n = 6, mean age = 78 ± 5, range = 71 to 85, M/F = 2/4, PMI = 16 ± 9) were obtained
from the Neuropathology & Molecular Genetics Core of the UCLA Alzheimer’s Disease
Research Center.
We dissected frozen brain samples into gray and white matter and extracted
loosely bound and non-heme iron according to the method of Nelson et al. [21] with
slight modifications. The hippocampus consisted of a 6-8 mm tissue block from its mid
portion, sampled at approximately the level (coronal) of the lateral geniculate nucleus,
and included the hippocampus proper, parahippocampal gyrus and entorhinal cortex.
Small wedges of white matter were dissected out from areas around the temporal horn
and within the parahippocampal gyrus in a caudo-rostral direction. Regions of the frontal
cortex that were sampled correspond to Brodmann areas 10 and 11. For loosely bound
iron, tissues were homogenized in 180 pi of 0.5 mM EDTA, and samples were
centrifuged at 13,000 x g for 10 min, after which 34 pL of 20% tricholoroacetic acid
(TCA)/0.5 mM EDTA was added to 120 pL of the supernatant. Then samples were
vortexed, centrifuged again at 13,000 x g for 10 min, and the supernatant collected and
stored at -20 °C. For non-heme iron, tissues were homogenized in 360 pL of 6% TCA/0.5
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mM EDTA and incubated at 90 °C for 30 min. Then 0.7 ml of 0.5 mM EDTA was added,
samples were centrifuged at 13,000 x g for 10 min, and the supernatant was collected and
stored at -20 °C. For total iron and copper, tissues were wet ashed according to the
method of Maynard et al. [20]. All metals were measured in duplicate by graphite
furnace atomic absorption spectrometry (GFAAS) with a SpectrAA 220Z (Varian,
Victoria, Australia).
Immunohistochemistry was done using the BioGenex Autostainer system (San
Ramon, CA) with 6 pm paraffin-embedded tissue sections from the hippocampus and
frontal cortex. Tissue sections were deparaffinized by two 15 min incubations in EZDeWax solution followed by antigen retrieval using the Antigen Retrieval Citra Plus
solution, both from BioGenex, according to the manufacturer’s instructions. Endogenous
peroxidase activity was inhibited by two 15 min incubations in 3% hydrogen peroxide in
10% methanol, and non-specific protein binding was blocked with Power Block
(Biogenex). Antibodies used are listed in Table 1. The anti-IRP2 antibody is now
available from Santa Cruz Biotechnology (Santa Cruz, CA). After 30 min incubations
with the respective antibodies, sections were washed with PBS and incubated for 20 min
with biotinylated secondary antibodies, followed by HRP-conjugated streptavidin.
Immunoreactivity was revealed using AEC as the chromogen.
Data are presented as means ± SEM. Statistical analysis was performed using
one-way ANOVA followed by the Tukey post hoc test with SPSS 12.0.1 software.
Corrections for age were done using ANCOVA analysis. P < 0.05 was considered
significant.
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Table 5 Antibodies used for immunohistochemistry.
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antibody

antigen

species

type

clone

source

dilution

IRP2
PHF-tau
A(340
A(B42
g-synuclein

138-200aa of IRP2
PHF-tau
C-terminal 7aa from A(340
C-terminal 6aa from Af342
Lewy bodies from patients with DLB

mouse
mouse
rabbit
rabbit
mouse

monoclonal
monoclonal
polyclonal
polyclonal
monoclonal

4G11
ATS
NA*
NA*
LB509

this study
Pierce
Chemicon
Chemicon
Zymed

1:100
1:40
1:100
1:100
1:50

*Not-applicable
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Results
Levels of loosely bound iron were similar between the frontal cortex and
hippocampus although concentrations in the white matter tended to be higher than in the
gray matter in both regions in all groups (Figure 3). We found no differences in the levels
of loosely bound iron in the frontal cortex between elderly controls, mild-moderate AD,
severe AD, and DLB. However, there was a significant decrease of loosely bound iron in
the hippocampal white matter in mild-moderate and severe AD brains compared to
controls (3.7 ± 0.4 and 3.7 ± 0.3, respectively, vs. 5.2 ± 0.6 pg Fe/g wet weight) which
remained significant when corrected for age in severe AD but was reduced to a trend in
mild-moderate AD.
Non-heme and total iron were also consistently higher in the white matter
compared to the gray matter with slightly higher levels in the frontal white matter
compared to that of the hippocampus in all groups (Figure 4 and 5). No significant
difference in non-heme and total iron was found between the groups in both regions
except for higher total iron in the frontal gray matter in DLB compared to controls when
corrected for age.
Levels of total copper were higher in the frontal cortex compared to the
hippocampus in normal brains (Figure 6). This difference is abolished in severe AD and
DLB. Compared to controls, total copper in severe AD and DLB was significantly lower
in the frontal gray matter (6.9 ± 1.2 vs. 3.9 ± 0.3 and 3.6 ± 0.6 pg Cu/g wet weight,
respectively) although this was reduced to a trend when corrected for age. No differences
in total copper concentrations were seen between any of the groups in the hippocampus.
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Figure 3. Loosely bound iron was decreased in the hippocampal white matter of mildmoderate and severe AD brains compared to controls. Data are presented as mean (pg
Fe/g wet weight) ± SEM and n values for each group are shown below the bars. *When
corrected for age differences between groups, the decrease in loosely bound iron in the
hippocampal white matter in severe AD remained significant (p = 0.033) whereas that for
mild-moderate AD was reduced to a trend (p = 0.052).
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Figure 4. There was no statistically significant difference in non-heme iron between in
the frontal cortex and hippocampus of elderly controls, mild-moderate AD, severe AD,
and DLB. Data are presented as mean (pg Fe/g wet weight) ± SEM and n values for each
group are shown below the bars. *When corrected for age differences between groups,
the trend toward increased non-heme iron in the hippocampal gray matter in severe AD
disappeared.
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Figure 5. Total iron in the frontal cortex and hippocampus of elderly controls, mildmoderate AD, severe AD, and DLB. Data are presented as mean (pg Fe/g wet weight) ±
SEM and n values for each group are shown below the bars. *When corrected for age
differences between groups, there was a significant increase in total iron in the frontal
gray matter in DLB compared to controls (p = 0.048).
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Figure 6. Total copper was decreased in the gray matter of the frontal cortex in severe
AD and DLB compared to controls. Data are presented as mean (pg Cu/g wet weight) ±
SEM and n values for each group are shown below the bars. *When corrected for age
differences between groups, the decreases in total copper in the frontal gray matter in
severe AD and DLB were reduced to trends (p = 0.057 for both groups) while the trends
toward decreased total copper in the frontal white matter disappeared.
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IRP2 expression was found to be primarily intraneuronal with sparing of
leptomeninges, oligodendrocytes, astrocytes, and white matter tracts. IRP2 expression
was limited to the cytoplasm of neurons in the gray matter of the frontal cortex and
pyramidal neurons in the hippocampus. The dentate gyrus was generally negative and
expressed IRP2 only in rare instances. We did not find significant differences in IRP2
expression between controls, mild-moderate AD, severe AD, and DLB (Figure 7), and
1RP2 did not colocalize with senile plaques, NFT, or Lewy bodies in the cases we
examined (data not shown).

Discussion
The purpose of this study was to more closely examine alterations in iron and
copper levels in AD at different stages of the disease. The decrease in loosely bound iron
levels in the hippocampal white matter in cases with mild-moderate AD and severe AD
but not DLB compared to elderly controls suggests that alterations in loosely bound iron
may occur relatively early in AD and be specific to this disease process. Our results are
consistent with a previous study that showed decreased transferrin and iron in AD white
matter [8] and may be a cause or consequence of myelin breakdown and oligodendrocyte
damage observed in AD [2,25]. Oligodendrocytes have high basal metabolism, which is
needed for lipid synthesis, and consequently show vulnerability to oxidative stress. Not
surprisingly, these cells contain the highest levels of iron out of all cell types in the brain,
and up to 70% of brain iron is associated with myelin [1,7]. Loosely bound iron is a
labile, chelatable pool of non-heme iron that mediates the transfer of iron from ferritin
storage sites to where it is needed for enzymatic and biosynthetic activity and includes
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Figure 7. IRP2 expression in the hippocampus of elderly control and AD brains. No
differences in the intensity or localization of IRP2 expression was seen in mild-moderate
AD, severe AD, or DLB brains compared to controls. A) Cytoplasmic IRP2 expression in
the CA1-2 hippocampal neurons in a severe AD patient (arrows); arrowheads show
absence of staining in small glial cells (x200). B) Absence of IRP2 expression in the
hippocampal dentate neurons (arrowhead) in a severe AD patient (x200). C) Absence of
IRP2 expression in the hippocampal CAS neurons (arrowhead) in a severe AD patient
(x200). D) Absence of IRP2 expression in the ependymal cells (arrowhead) in a severe
AD patient (xlOO). E) Cytoplasmic IRP2 expression in the CA4 hippocampal neurons
(arrows) in an elderly control brain (x200).
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iron attached to phosphate esters and carbohydrates [11,16]. Iron deficiency causing poor
myelination is associated with mental deficits in children [1], and decreased myelin basic
protein has been shown to correlate with cognitive decline in AD [29]. Our findings of
decreased loosely bound iron in the white matter of the hippocampus, a region generally
affected in the initiating stages of the disease, are in agreement with an early loss of
oligodendrocytes in AD [5].
Non-heme iron consists of iron tightly bound to proteins such as the iron transport
proteins transferrin and lactoferrin and in intracellular storage proteins such as ferritin
[11,13,17]. The majority of iron in the hippocampal gray matter was non-heme, in
agreement with previous studies showing that most iron in the hippocampus is ferritin
like [10]. The lack of major differences in non-heme and total iron levels between the
groups suggest a relocalization and sequestering of iron into plaques rather than a general
increase in bulk tissue as high concentrations of iron have been consistently reported in
amyloid plaques [6,19]. These results are consistent with previous reports that have found
no difference in non-heme and total iron concentrations in bulk tissue from AD and
control brains [12,23] but at variance with others who have reported increases in non
heme and total iron in AD brain. Total protein levels have been demonstrated to be
significantly decreased in AD frontal cortex [18] which may partly explain some of the
increases in iron found when measured per milligram of protein. However, further studies
with larger sample sizes will be necessary to confirm changes in non-heme and total iron.
IRP2 expression was confined to neurons in the gray matter and did not differ between
controls, AD, and DLB, in the frontal cortex and hippocampus, which is consistent with
the lack of major differences in iron levels in the gray matter of both regions.
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Compared to controls, copper levels in the frontal cortex were decreased in the
gray matter in severe AD and DLB. These results are in agreement with reports of
decreased levels of copper in the AD brain [9] and in the brains of transgenic mice
overexpressing APP [20]. The decrease in copper is not seen in mild-moderate AD but
only in severe AD, suggesting that this phenomenon may occur at a later stage in disease
progression. Overproduction of APP and Ap is hypothesized to pool copper into the
extracellular space from the intracellular compartment and thus cause a deficiency of
intracellular copper in AD brain [4,20]. Furthermore, increased levels of copper in CSF
and plasma have been found in AD patients in contrast to the decrease seen in brain
[3,28]. Mechanisms similar to that seen in AD brains may also underlie lower copper
levels in DLB, since both diseases share some common pathologic features. A limitation
of this and other post-mortem studies is their cross sectional nature, and thus we have
examined iron levels in the brains of AD patients at different stages of the disease. A
related limitation is the difficulty of obtaining tissue quickly after death although there
were no significant differences in the PMIs between our patient groups.
In conclusion, we found decreased iron in severe AD hippocampus and decreased
copper in the frontal cortex in severe AD and DLB while finding no significant
differences in IRP2 expression between the groups. These results lend further support to
the hypothesis of dysregulation of brain metals in AD and related dementias while
shedding light on the timeframe in which the alterations in iron and copper metabolism
occur in the pathogenesis of the disease.
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Abstract
Recent studies indicate that chronic inflammation plays a pathogenic role in both
the central nervous system (CNS) and periphery in Alzheimer’s disease (AD). We have
screened for cytokines differentially produced by peripheral blood mononuclear cells
(PBMCs) isolated from subjects with mild cognitive impairment (MCI) and mild AD
subjects who had progressed from MCI using a commercially available cytokine array.
Following determination of expressed cytokines, we quantified levels of the
proinflammatory cytokines TNF-a, IL-6, and IL-8, and the antiinflammatory cytokine IL10 using flow cytometry. We have found a significant increase in the levels of IL-6, IL-8,
and IL-10 produced by PBMCs stimulated for 24 hours with phytohemagglutinin (PHA)
in MCI subjects compared to healthy elderly controls. However, in PBMCs stimulated for
48 h with lipopolysaccharide (LPS), lower TNF-a/IL-10, IL-6/IL-10, and IL-8/IL-10
ratios were seen in MCI subjects. There were no differences in plasma levels of IL-8
between aged controls, MCI, and mild AD, and the levels of circulating IL-6 and IL-10
were below detection limits. Our data indicate that changes in cytokine production by
PBMCs may be detected early in MCI, and an alteration of the immune response may
precede clinical AD.
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1. Introduction
A chronic inflammatory process has been implicated in the neuropathology of
Alzheimer’s disease (AD), the most common form of dementia in the elderly. Both
neural and systemic alterations in the immune response have been reported (McGeer and
McGeer, 1998; Neuroinflammation Working Group, 2000; Richartz et ah, 2005).
Interleukin-1 (IL-1) is associated with amyloid-p (Ap) in senile plaques, hallmarks of AD
neuropathology, (Griffin et al., 1989, 1995) and also increases the synthesis and
translation of the mRNA for amyloid precursor protein (APP), the processing of which
produces Ap (Goldgaber et al., 1989; Rogers et al., 1999). Blood cells express APP
mRNA and protein (Allen et al., 1991; Schlossmacher et al., 1992), and APP mRNA is
increased in peripheral blood mononuclear cells (PBMCs) from AD patients compared
with cells from healthy elderly controls (Jiang et al., 2003). This could potentially be a
source for abnormal amyloid deposited in the brain (Allen et al., 1991; Reale et al.,
2005). On the other hand, exposure of Ap to cultured human monocytes was shown to
stimulate the production and release of IL-1 p and interleukin-1 receptor antagonist (ILIRa) (Meda, 1999). Compared to controls, lymphocytes from AD patients are less
responsive to stimulation with amyloid peptides which could suggest T cell anergy (Trieb
et al., 1996). However, it is unclear whether circulating amyloid is deposited in the brain
and causes neuroinflammation or immune activation to abnormal amyloid peptide in the
brain then triggers the peripheral immune response (Reale et al., 2005). Inflammatory
signaling pathways exist from the brain to the periphery, but the mechanism of induction
is unknown (De Simoni et al., 1990, 1995; Gottschall et al., 1992; Song et al., 1999).
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IL-1, IL-6, and IL-10 polymorphisms have been associated with altered cytokine levels
and risk for AD (Arosio et al, 2004; Nicoll et ak, 2000; Papassotiropoulos et ak, 1999). A
recent report demonstrated decreased production of the proinflammatory cytokines IL-6,
IL-12, interferon- y (IFN-y), and tumor necrosis factor-a (TNF-a) in whole blood cell
cultures of AD patients compared to age-matched controls, suggesting an attenuated
immune response (Richartz et ak, 2005). Moreover, decreased production of the anti
inflammatory cytokine IL-10 in PBMCs stimulated with Ap peptides was seen in AD
(Arosio et ak, 2004). However, other studies have shown elevated levels of TNF-a, IL1 (3, IL-6, and IL-10 (Lombardi et ak, 1999) and higher pro- to anti-inflammatory cytokine
ratios, both IL-lp/IL-10 and IL-6/IL-10, released from LPS stimulated whole blood
cultures from AD patients compared to controls, suggesting a proinflammatory
phenotype in AD (Remarque et ak, 2001). These seemingly contradictory reports may be
partly explained by changes in inflammatory phenotype that are specific to certain
disease stages as demonstrated by a study that found decreased production of IL-1 (3 and
IL-6 by stimulated blood cells in severe AD but not mild to moderate AD patients (Sala
et ak, 2003).
Increasing evidence suggests that peripheral modification of inflammatory factors
may occur early during the development of AD (Galimberti et ak, 2005; Huberman et ak,
1994; Tarkowski et ak, 2003). This may explain the results of several epidemiological
studies that suggest that non-steroidal anti-inflammatory drugs (NSAIDs) protect against
AD but do not have therapeutic effects (in f Veld et ak, 2001; McGeer et ak, 1996;
Pasinetti and Pompl, 2002). Many therapeutic studies target those with advanced stages
of AD at which point inflammatory processes may have already done the damage. Mild
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cognitive impairment (MCI) describes a pre-clinical stage of AD, applied to a transitional
period between normal aging and early AD (Petersen, 2004). An altered immune profile
has also been found in MCI patients. Serum monocyte chemotactic protein-1 (MCP-1), a
beta chemokine, was shown to be upregulated in MCI and mild AD but not in severe AD
patients as compared with controls (Galimberti et al., 2005). Furthermore, both MCI and
AD patients who had progressed from MCI had higher TNF-a (proinflammatory
cytokine) to TGF-f3 (anti-inflammatory cytokine) ratios in CSF when compared to
healthy controls, indicating a higher proinflammatory state in patients at risk for AD
(Tarkowski et al., 2003). Alterations in the immune response in MCI would suggest that
inflammatory events may precede the clinical development of AD.
Characterizing similar immune alterations in subjects with MCI, which represents
a preclinical stage of AD, will help clarify whether cytokine dysregulation is a cause or
consequence of AD as well as identifying potential biomarkers for MCI in easily
accessible peripheral blood cells. Our hypothesis is that alterations in peripheral immune
function, specifically cytokine production, are early events in the development of AD.
The purpose of this study was to detect cytokines that may be involved early in the
pathogenesis of AD by first screening for cytokines produced by PBMCs isolated from
healthy aged controls, subjects with MCI, and subjects who had progressed to mild AD
from MCI, using a commercially available array of 20 cytokines involved in
inflammation. Following determination of expressed cytokines, we quantified levels of
the proinflammatory cytokines TNF-a, IL-6, and IL-8 and the anti-inflammatory cytokine
IL-10 produced by unstimulated and stimulated (with PHA or LPS) PBMCs from
controls, MCI, and mild AD subjects using flow cytometry. In general, PHA stimulates
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lymphocyte proliferation, while LPS stimulates monocytes to release IL-1 and TNF-a
(Hsu and Wen, 2002; Tyrsted and Munch-Petersen, 1977; Zhu et ah, 2000). Reports that
demonstrate a difference in PBMC cytokine production between AD patients and
controls have used different stimulants including PHA and LPS and various time points,
including 24 and 48 hour incubations (Richartz et ah, 2005; Remarque et ah, 2001;
Huberman et ah, 1994). Because we designed this study as a comprehensive assessment
of alterations in MCI subjects that have been previously reported in AD patients, both
stimulants and time points were used. Examining PBMC response to different stimuli
will allow us to determine the relative effect of both cell types in an environment that
allows for their interaction and more closely reflects the in vivo state. To our knowledge,
this is the first study to examine the PBMC cytokine profile from MCI subjects.

2. Materials and Methods
2.1. Subjects
Blood samples were obtained from 31 subjects with MCI (mean age 75.06 ± 1.34,
male/female 15/16), seven mild AD subjects who had their blood drawn after they had
progressed to mild AD from MCI (79.14 ± 0.99, 3/4), and 21 healthy aged controls
(73.10 ± 1.57, 8/13). There was no significant difference in age between MCI subjects
and controls. However, the mild AD group was statistically older than the control group
(p < 0.05). All subjects included in the study have undergone extensive physical and
psychometric evaluations including blood tests, MRI, mini-mental state examination
(MMSE), Logical Memory I and II tests, and clinical dementia rating (CDR). MCI was
diagnosed following the guidelines by Peterson (2004). Classification of MCI is based on
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either abnormal memory determined by the Logical Memory II subscale or a CDR
memory score of 0.5-1.0 which is based both on performance and informant data. All
MCI cases were subtyped as amnestic multiple domain MCI.
Subjects with dementia, neurological disease, history of major head trauma,
DSM-IV major depression within the past year, any unstable medical condition, history
of schizophrenia, and history of alcohol or substance abuse were excluded. Subjects
taking neuroleptics, chronic anxiolytics, or sedative hypnotics were also excluded from
the study.
Protocols for collecting blood samples were approved by the Institutional Review
Board of Loma Linda University School of Medicine and informed consent was obtained
from all subjects.

2.2. Cell isolation and culture conditions
Blood was drawn from each subject into 10 ml heparin Vacutainer tubes from BD
Biosciences (San Diego, CA). PBMCs were isolated by Ficoll-Hypaque density gradient
centrifugation and resuspended in RPMI 1640 medium supplemented with 10% fetal
bovine serum, nonessential amino acids, 1 mM sodium pyruvate, 50 U/ml penicillin and
50 mg/ml streptomycin in 12 well plates at 106 cells/ml. Cells were cultured for 24 or 48
hours at 37 °C in 5% CO2 in complete culture medium alone or stimulated with 2 pg/ml
phytohemagglutinin (PHA) or 10 pg/ml lipopolysaccharide (LPS), concentrations and
time points commonly used to optimally induce cytokine production (Arosio et al., 2004;
Huberman et al., 1994; Lombardi et al., 1999). After incubation, samples were
centrifuged and supernatants collected and stored at -70 °C until assayed.
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2.3. Cytokine array
Human cytokine array membranes coated with 20 specific cytokine antibodies
(Fig. 1A; ChemiArray™ Human Inflammation Antibody Array I, Chemicon, Temecula,
CA) were probed with cell culture supernatants from PBMCs stimulated for 48 hours
with LPS from controls, MCI, and mild AD according to the manufacturer’s instructions.
This array uses a solid-phase sandwich technique to screen for multiple cytokines at once
and is based on capture and detection antibodies directed against different cytokines in a
combination ELISA/Immunoblotting method. Samples are incubated on a membrane
coated with immobilized antibodies against different cytokines to which a cocktail of
biotinylated cytokine antibodies are added to form the antibody “sandwich”. Then, HRPconjugated streptavidin is added and membranes visualized with chemiluminescence,
each duplicate spot on the membrane corresponding to a different cytokine. Briefly,
membranes were blocked by incubating with the blocking buffer for 30 min and then
incubated with sample for 1.5 h, both at room temperature. Membranes were washed with
Wash Buffer I (3x, 5min each) then with Wash Buffer II (2x, 5min each) and incubated
with biotin-conjugated antibodies overnight at 4°C. Finally, membranes were washed,
incubated with HRP-conjugated streptavidin for 2 h at room temperature, and incubated
with detection buffer for 2 min. Membranes were exposed to X-ray film (Biomax XAR
film, Kodak, New Haven, CT) and developed. Average signal density for each cytokine
was determined by densitometric analysis using Chemilmager 440 (Alpha Innotech, San
Leandro, CA), and signals were normalized to the positive controls on the same
membrane.
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2.4. Cytokine measurement in cell culture supernatant
Levels of IL-12p70, TNF-a, IL-10, IL-6, IL-1(3, and IL-8 in cell culture
supernatants were determined using the Cytometric Bead Array Assay (Becton Dickinson
Biosciences, San Diego, CA), according to the manufacturer’s instructions by flow
cytometry (FACSort flow cytometer and CellQuest software, Becton Dickinson,
Sunnyvale, CA). The instrument was calibrated with CaliBrite beads before each analysis
(BD Biosciences, San Diego, CA). Since IL-1|3/IL-10 and IL-6/IL-10 ratios have
previously been used as indicators of the inflammatory phenotype (Remarque et al.,
2001), ratios of each of the proinflammatory cytokines TNF-a, IL-6, IL-1(3, and IL-8 to
the anti-inflammatory cytokine IL-10 were also calculated to assess propensity to
inflammation.

2.5. Cytokine measurement in plasma by ELISA
Plasma samples were collected and analyzed for IL-6, IL-8, and IL-10 using
commercially available ELISA kits (Endogen, Woburn, MA) according to the
manufacturer’s instructions. The assay sensitivity was <1 pg/ml for IL-6, <2 pg/ml for
IL-8, and <3 pg/ml for IL-10.

2.6. Statistical analysis
Data are presented as means ± S.E.M. Statistical analysis was performed using the
SPSS 12.0.1 software. Since cytokines are known to have a non-Gaussian distribution
(De Luigi et al., 2002; Lombardi et al., 1999), differences among cytokine production
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were evaluated using the non-parametric Mann-Whitney U test. A P value of <0.05 was
chosen to indicate significance.

3. Results
3.1. Cytokine array
Cell culture supernatants from PBMCs, stimulated for 48 hours with LPS, from
elderly controls (n = 6), MCI (n = 4), and mild AD subjects (n = 3) were screened for
cytokines involved in inflammation. Out of the 20 cytokines assayed for, one or more
subjects expressed IL-1(3, IL-2, IL-6, IL-8, and IL-10 (Figure 8). However, only one mild
AD case out of three, two control subjects out of six, and no MCI subjects expressed IL2. Therefore, IL-2 was excluded from further study. Only one out of six control cases
showed detectable levels of IL-10 expression, but all four MCI patients and two out of
three mild AD cases expressed IL-10. IL-6 production by LPS stimulated PBMCs from
MCI subjects was significantly higher compared to elderly controls (p < 0.03) (Figure 9).
No significant differences were seen in the other cytokines, only a trend indicating lower
IL-lp and IL-6 levels in mild AD versus MCI.

3.2.1L-I2p70, TNF-a, IL-10, IL-6, IL-1(3 and IL-8 production
The levels of IL-6, IL-8, and IL-10 produced by PBMCs stimulated for 24 h with
PHA were significantly higher in MCI patients compared to elderly controls (p < 0.03 for
all three cytokines) (Table 6). This difference disappears after cells are cultured for 48 h.
In contrast, there were no significant differences between groups in absolute cytokine
concentrations when PBMCs were stimulated with LPS. However, pro- to anti-
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Figure 8. (A) Alignment of 20 cytokines on the human cytokine array membrane.
Abbreviations: GCSF: granulocyte colony stimulating factor; GM-CSF: granulocyte
macrophage-colony stimulating factor; IFN: interferon; IL: interleukin; TIMP: tissue
inhibitors of metalloproteinase. (B) Representative examples of cytokine array
membranes probed with the cell culture supernatants of 48 h LPS stimulated PBMCs
from mild AD, MCI, and control. Each dot represents immunoreactive staining for the
respective cytokines.

85

—h r-? on '=i- l-i

vd

c-- oo

• •
&0
U-,

4

■

<C

<D
o

• •

^3

t'Jj
U-i

*#

# H
■

l-H

>J

o

Figure 9. Densitometric quantification of cytokine levels from the cytokine arrays in
elderly controls (n = 6), MCI (n = 4), and mild AD subjects (n = 3). To compare results
between different membranes, the signals (average density) for each cytokine were
normalized to the positive controls on each membrane. Two out of three mild AD cases
had detectable levels of IL-10 expression, but only one out of six control cases showed
IL-10 expression. All MCI subjects showed detectable levels of IL-lp, IL-6, IL-8, and
IL-10. Dashed lines indicate the detection limit (0.53), */> < 0.03, significantly different
from controls.
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inflammatory cytokine ratios, TNF-a/IL-10, IL-6/IL-10, and IL-8/IL-10, after stimulation
with LPS for 48 h were significantly lower in MCI compared to controls (p < 0.03, p <
0.01, andp < 0.05, respectively) (Table 7). No differences in cytokine ratios were seen in
PHA stimulated PBMCs between groups as expected since both the proinflammatory
cytokines IL-6 and IL-8 and anti-inflammatory cytokine IL-10 were increased in MCI
compared to controls. Cytokine levels were below the limit of detection in unstimulated
PBMCs cultured for 24 or 48 h except for IL-8, and IL-8 levels did not differ between
elderly controls, MCI, and mild AD subjects (data not shown).

3.3. IL-6, IL-8 and IL-10 levels in plasma measured by ELISA
There were no significant differences in the levels of IL-8 between elderly
controls (n = 13, average ± SEM = 10.2 ± 4.5 pg/ml), MCI subjects (n = 15, average ±
SEM = 6.2 ± 2.5 pg/ml), and mild AD subjects (n = 7, average ± SEM = 9.9 ± 4.1 pg/ml).
No detectable levels of IL-6 and IL-10 were found in plasma in any of the three groups.
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Table 6 Cytokine production by PBMCs from elderly controls, MCI, and mild AD
subjects stimulated for 24 h or 48 h with PHA or LPS. All data are presented as mean
(SEM) and are expressed in pg/ml; */? < 0.03, significantly different from controls; **p <
0.03, significantly different from MCI; ND, non-detectable.
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Table 7 Cytokine parameters of PBMCs from healthy aged controls, MCI, and mild AD
subjects stimulated for 24 h or 48 h with LPS or PHA. All data are presented as mean
(SEM), */> < 0.03, significantly different from controls.
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IL-ip/IL-10
mean (SEM)
3.08(0.68)
2.38(0.40)
3.42(1.09)

n
14
22
7

IL-6/IL-10
mean (SEM)
5.46(3.07)
18.71(5.92)
5.34(3.06)

n
15
22
7

2.59(0.63)
2.97(0.62)
3.31(0.83)

16
19
5

10.66(4.86)
19.34(6.22)
7.90(3.13)

12
17
2

1.66(0.21)
1.69(0.32)
0.69(0.62)

17
20
7

6.83(1.40)
5.21(0.74)
5.76(1.37)

16
16
6

78.10(10.52)
75.78(17.34)
76.15(16.22)

16
19
7

15.77(3.03)
12.93(2.08)
13.65(3.70)

18
22
6

2.71(0.39)
1.78(0.51)*
1.50(0.46)

17
17
5

95.69(9.98)
62.66(14.50)*
69.43(13.28)

18
21
6

Ratio
24h PHA
Control
MCI
Mild AD

n
15
22
7

48h PHA
Control
MCI
Mild AD

16
19
5

24h LPS
Control
MCI
Mild AD
48h LPS
Control
MCI
Mild AD

TNF-a/IL-10
mean (SEM)
3.35(0.65)
3.74(0.88)
2.97(0.93)
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13.15(2.23)
10.30(1.55)
6.57(1.80)

n
14
19
6

IL-8/IL-10
mean (SEM)
393.8(67.31)
766.5(161.3)
273.3(120.4)

16
17
5

529.0(90.47)
548.1(103.7)
985.7(272.1)

16
15
6

348.8(52.26)
272.5(36.54)
469.6(95.78)

14
16
5

650.7(92.41)
365.9(65.38)*
573.3(122.6)

4. Discussion
In our investigation of cytokine production by cultured PBMCs from healthy
elderly controls, MCI and mild AD subjects, we found that levels of IL-6, IL-8, and IL10 were significantly higher in MCI subjects compared to controls when cells were
stimulated with PHA for 24 h but not 48 h. Since chronic inflammation is implicated in
AD, PBMC response to stimulants was examined at two time points, 24 and 48 h. The
inability to detect differences at 48 h after PHA stimulation may be due to cytokine
release reaching a plateau in both groups and could suggest that cells from MCI subjects
are more easily stimulated to produce cytokines but that production in controls reach
similar levels to MCI over time. The concomitant increase in the anti-inflammatory
cytokine IL-10 may be in response to increased proinflammatory cytokines IL-6 and IL-8
as IL-10 inhibits most cytokines involved in inflammation, including IL-1, IL-6, TNF-a,
and IL-8 (Grutz, 2005; Moore et ah, 2001). No differences in absolute cytokine
concentrations were seen when cells were stimulated with LPS at either time point.
However, stimulation with LPS for 48 h resulted in TNF-a/IL-10, IL-6/IL-10, and IL8/IL-10 ratios significantly lower in MCI compared to controls which may indicate a
faster attenuation in the production of inflammatory cytokines with respect to IL-10. This
is in contrast to cells stimulated with PHA. PHA stimulates the proliferation of
lymphocytes, increasing DNA polymerase activity after incubation for 15 h (Tyrsted and
Munch-Petersen, 1977), while LPS stimulates monocytes to release IL-1 and TNF-a (Hsu
and Wen, 2002; Zhu et al., 2000). Even though the effect of interactions between cell
types cannot be excluded since both lymphocytes and monocytes were cultured together,
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the differential effect of PHA and LPS suggests alterations in cytokine production in MCI
specific to immune cell type.
It has been shown that PHA stimulated PBMCs of moderately severe AD patients
secrete significantly higher levels of IL-2 compared to mild AD and age-matched
controls while levels of IL-lp do not differ between the groups (Huberman et ah, 1994).
Also, Lindberg et al. (2005) have found no differences in CSF or serum levels of the
soluble form of IL-1 receptor type II (sIL-lRII) in both the early and late stages of AD
when compared to controls and have suggested that the IL-1 system appears intact in both
the early and late stages of AD. Similarly, we did not find any significant difference in
IL-1 (3 production between elderly controls, MCI and mild AD subjects. TNF-a and IL-6
release from blood cells stimulated with LPS was shown to be downregulated in AD (De
Luigi et al., 2002). This is in agreement with our findings that TNF-a/IL-10 and IL-6/IL10 ratios were lower in MCI compared to controls, showing that depressed production of
these pro inflammatory cytokines with respect to IL-10 in LPS but not PHA stimulated
PBMCs can be detected early in the preclinical stage of AD. The lack of differences we
found between controls and mild AD patients must be interpreted with caution since the
sample size was small. However, our findings of inflammatory markers changing in MCI
and returning near normal levels in mild AD are in agreement with reports that show
increased chemokine interferon-y-inducible protein 10 in CSF from MCI but not AD
(Galimberti et al. 2006), decreased production of cytokines in whole blood cultures from
AD (Richartz et al., 2005), and decreased IL-1 (3, IL-6, and TNF-a release from LPS
stimulated peripheral blood from severe AD patients but no difference between mild and
moderate AD patients and controls (Sala et al., 2003). This also correlates with the
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findings of Griffin et al. (1995) in which IL-la+ microglia associated with plaques were
found to increase in earlier plaque stages but then decrease in later plaque stages of AD,
suggesting that microglia and inflammation play early roles in plaque evolution.
However, inflammatory processes in the brain may not have a simple direct relationship
with that in the periphery and evidence points to a more complex relationship between
brain and peripheral inflammation.
In sum, the results indicate that alterations in cytokine production by PBMCs can
be detected in MCI and could precede the development of clinical AD. However, this
may not be entirely explained by a shift toward the proinflammatory phenotype as the
anti-inflammatory cytokine IL-10 was increased along with IL-6 and IL-8 when cells
were stimulated with PHA. Interestingly, the trend in PHA stimulated cytokine
production seems to peak in MCI subjects and return to control or below control levels
once they progress to early AD. This is in agreement with findings that intrathecal
inflammation is seen before the development of AD (Tarkowski et al., 2003). Paganelli et
al. (2002) have found that the level of serum TNF-a is significantly lower in mildmoderate AD compared to severe AD and vascular dementia suggesting a difference in
the cytokine profile at different stages of AD as well as between other types of dementia.
Our data support the hypothesis that inflammation is an early event rather than a late
consequence of the disease (Galimberti et al., 2005; Tarkowski et al., 2003).
IL-6 is released in response to TNF-a and IL-1 but persists longer than these
cytokines in plasma and so is a useful indicator of proinflammatory cytokine activation
(Song and Kellum, 2005). At the same time, the involvement of IL-6 in several diseases
with an inflammatory component, and the heterogeneity of MCI subjects resulting in a
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high SEM of IL-6 production seen in our study would preclude the use of IL-6 by itself
as a biomarker for MCI. Most likely a panel of markers, including IL-6, IL-10, IL-8, and
other potential markers of MCI such as serum MCP-1 (Galimberti et ah, 2005) will be
needed to selectively diagnostic MCI. Production of IL-6, IL-1, TNF-a, and IL-8 but not
IL-10 in microglia is stimulated by Af3 (Franciosi et al., 2005; Nagai et al., 2001). In
peripheral blood monocytes, A(3 stimulates the release of IL-1 p, interleukin-1 receptor
antagonist (IL-IRa) but not of IL-6, IL-10, and TGF-p (Meda, 1999). Also, B cells from
AD patients have been demonstrated to produce A{3 reactive autoantibodies (Gaskin et
al., 1993). Song et al. (2001) have shown that intracerebroventricular injection of A(3 into
mice cause increased levels of IL-6 in both brain and plasma which implicates that
deposition of A{3 in the CNS may be linked to altered peripheral immune responses.
Furthermore, transgenic mice chronically expressing human APP have decreased
lymphocyte proliferation and production of cytokines in response to Ap (Monsonego et
al., 2001). Together with the finding that lymphocytes from AD patients are less
responsive to stimulation with amyloid peptides compared to controls (Trieb et al., 1996),
this

could

suggest that chronic

Ap

exposure

leading to

cellular immune

hyporesponsiveness to Ap may exacerbate its accumulation in AD (Sala et al., 2003). To
our knowledge, there have been no studies that have examined modulation of cytokine
release from PBMCs by Ap in MCI subjects. We will focus our future work on the
effects of Ap on PBMC cytokine production in MCI.
In conclusion, our results show an increased production of the proinflammatory
cytokines, IL-6 and IL-8, and the anti-inflammatory cytokine IL-10 in MCI patients
compared to elderly controls. This indicates an alteration in the cytokine profile in the
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preclinical stages of AD which may help to elucidate the role of inflammation and also
aid in the design of therapeutics for this devastating disease.
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Abstract
Alterations in the peripheral immune system are associated with dementia and the
neuropathology of Alzheimer’s disease, but have yet to be studied early in the disease
process. To test the hypothesis that the balance of immune cell phenotypes is disrupted
in the early progression of memory deterioration, patients with mild cognitive impairment
(MCI) and healthy elderly controls were examined for the distribution of subpopulations
of leukocytes (lymphocytes, granulocytes, and monocytes) and lymphocyte subtypes
(helper/inducer and suppressor/cytotoxic T lymphocytes and B lymphocytes) in blood.
MCI subjects had a significantly higher percentage of total lymphocytes and a lower
percentage of granulocytes compared to elderly controls. Furthermore, the expression of
cell surface amyloid precursor protein (APP) and intracellular amyloid-p peptide (Ap) in
lymphocytes and monocytes were determined. We found lymphocyte APP expression to
be significantly increased in MCI subjects compared to controls. Our data indicate that
changes in immunological parameters may be detected early in MCI, and an alteration of
the immune response may precede clinical AD.
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1. Introduction
Age-associated neural and circulatory alterations in the immune system have been
reported in Alzheimer’s disease (AD), the most common form of dementia in the elderly
(McGeer & McGeer, 1998; Richartz et ah, 2005). Inflammatory cytokines, activated
microglia, and immigration of certain T lymphocytes are found in association with AD
neuropathologies, including amyloid plaques and neurofibrillary tangles (McGeer et ah,
1989; Griffin et ah, 1995; Singh, 1997; Neuroinflammation Working Group, 2000), and
alterations in peripheral immune cells are also reported in patients with AD. The
proportion of both CD4+ (Lombardi et al,. 1999) and CD8+ lymphocytes have been
shown to be decreased in AD relative to healthy aged-matched controls (Pirttila et ah,
1992). Furthermore, Shalit et ah (1995) have demonstrated that in moderately severe, but
not mild AD patients, there was a significant decrease in lymphocyte proliferation
compared to controls. A decrease in proliferation in peripheral blood mononuclear cells
(PBMCs) of AD patients has also been found (Lombardi et ah, 1999). However, other
reports indicate no differences in either CD4/CD8 ratios (Ikeda et ah, 1991), total
lymphocytes (Dysken et ah, 1992) or the percentage of CD3+ lymphocytes (total T
lymphocytes) (Lombardi et al,. 1999) between AD and controls. Differences in
methodology or heterogeneity in the selection of patients with respect to the severity of
dementia may partly account for these differences.
Changes in functional responses by peripheral leukocytes have been linked to
pathological processes that occur in the AD brain. Trieb et ah (1996) have shown that
lymphocyte proliferation is stimulated by amyloid precursor protein (APP), the
processing of which produces amyloid-p (Ap) peptide, the major component of amyloid
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plaques (Mott et al., 2005), in control but not AD patients. Leukocytes also express APP
mRNA and protein (Allen et al., 1991; Schlossmacher et al., 1992; Bullido et al., 1996),
and APP expression on lymphocytes and monocytes can be increased with activating
signals (Li et al., 1999; Bullido et al., 1996). Moreover, APP mRNA in PBMCs and APP
protein in lymphocytes and monocytes have been found to be elevated in AD patients
compared to controls (Jiang et al., 2003). Functional changes in APP production and
processing in peripheral immune cells may reflect dysregulation of APP metabolism in
the brain (Pallister et al., 1997; Jung et al., 1999). Recently Migliore et al. (2005)
demonstrated increased DNA damage in peripheral leukocytes of subjects with mild
cognitive impairment (MCI) and AD patients compared to controls, suggesting the
possibility that alterations in peripheral blood cells may be an early event in AD. MCI is
a pre-clinical stage of AD representing a transition state between normal aging and early
AD (Petersen, 2004). However, no study has examined peripheral blood cells in subjects
with MCI even though a significant proportion of these patients eventually transition into
mild AD.
Development of early biomarkers for diagnosis and potential intervention in
patients with MCI has promise for providing a definite diagnosis of people at risk for
developing AD. Thus, the main hypothesis addressed by the present study is that
dysregulation of peripheral immune responses are early events in AD pathogenesis and
can be detected in subjects with MCI. The approach was to determine if alterations in
leukocyte immunophenotypes and peripheral blood cell expression of APP and A(3,
critical markers for AD, occur in MCI subjects.
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2. Materials and Methods
2.1. Subjects
In this study, we investigated 48 subjects that met criteria described below for
MCI (mean age 77.3 ± 5.2, male/female = 28/20, years of education = 14.3 ± 2.3) and 24
healthy aged controls (mean age 73.6 ± 7.2, male/female = 9/15, years of education =
13.7 ± 2.7). MCI and controls subjects were recruited by referrals from neurologists,
internists, geriatricians, and family practitioners and through advertisement in the local
media in the Southern California area. The investigation was carried out in accordance
with the Declaration of Helsinki, informed consent was obtained from all subjects, and
protocols for collecting blood samples were approved by the Institutional Review Board
of Loma Linda University School of Medicine. Following initial screening with the mini
mental state examination (MMSE) and Logical Memory I and II tests, all subjects
selected for inclusion in the study underwent a full neuropsychological battery of tests
including clinical dementia rating (CDR), North American Reading Test, Verbal Fluency:
Phonological and Semantic tests, Wisconsin Card Sorting Test, Trailmaking Test A & B,
Boston Naming Test, Depressive Features Battery Version II and the Geriatric
Depression Scale. Physical evaluations were also performed including blood tests and
MRI. MCI was diagnosed following the guidelines by Grundman et al. (2004). MCI was
defined as either abnormal memory determined by scoring below the education adjusted
cutoff on the delayed paragraph recall Logical Memory II subtest of the Wechsler
Memory Scale - Revised (Wechsler, 1987) (maximum score = 25, cutoff scores: less than
or equal to 8 for 16 or more years of education, less than or equal to 4 for 8-15 years of
education, less than or equal to 2 for 0-7 years of education) or a CDR memory score of
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0.5-1.0 which is based on both performance and informant data. All MCI cases were
subtyped as amnestic MCI. In brief, all MCI subjects have memory complaints confirmed
by either logical memory or CDR informant scoring (CDR = 0.5), global CDR of 0.5,
abnormal memory for age, normal activities of daily living, normal general cognitive
function, and no dementia. All control subjects were without objective memory
impairment, have a CDR memory component of 0, global CDR of 0, and were within
normal ranges in neuropsychological tests. All subjects had normal thyroid function and
vitamin B12 levels. Subjects were excluded from the study when clinical symptoms of
other dementias, neurological diseases, history of major head trauma, or DSM-IV major
depression were present within the preceding 12-month period. Individuals with an
unstable medical condition, history of schizophrenia, and history of alcohol or substance
abuse, medicated with neuroleptics, chronic anxiolytics, or sedative hypnotics were also
excluded. There was no evidence of acute illness at the time of clinical evaluation or
blood drawing and no significant difference in the incidence of medical comorbidities,
including hypertension, diabetes and coronary heart disease (CHD) between controls and
MCI subjects (percentage of subjects previously diagnosed with hypertension: 17%
control and 25% MCI; diabetes: 0% control and 4% MCI; and CHD: 4% control and 6%
MCI).

2.2. Immunophenotyping
Blood was drawn from each subject into ACD Vacutainer tubes (8.5ml;
containing 1.5 mL of trisodium citrate [22.0g / L], citric acid [8.0 g / L], and dextrose
[24.5 g / L]) between 8 am and 12 pm in the morning to avoid the influence of circadian
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rhythm on lymphocyte subpopulations. The immunophenotyping panel consisted of the
following labeled monoclonal antibody (mAb) combinations: IgG]-FITC/IgGi-PE/CD45Cy5PE (leukocytes), CD45-FITC/CD14-PE/CD3-Cy5PE (total T lymphocytes), CD3FITC/CD4-PE/CD45-Cy5PE
PE/CD45-Cy5PE

(helper/inducer

(suppressor/cytotoxic

T

T

lymphocytes),

lymphocytes),

and

CD3-FITC/CD8CD3-FITC/CD19-

PE/CD45-Cy5PE (B lymphocytes). A 0.1 ml aliquot of blood was incubated with each
mAb combination for 20 min in the dark at room temperature (RT). Erythrocytes were
lysed with 2 ml of lx VitaLyse (BioE, St. Paul, MN) for 60 min in the dark at RT, and
centrifuged at 1000 xg for 1 min. Lysate was decanted, cells were vortexed vigorously to
resuspend the pellet, and then washed with 2 mL of lx PBS, repeating the centrifugation
and decanting. Cells were resuspended in 0.5 ml lx PBS and immediately analyzed on a
FACSort flow cytometer. CellQuest software (Becton Dickinson, Sunnyvale, CA) was
used for data analysis. Electronic gates were set to define total leukocytes: forward scatter
(FS, relative cell size) /side scatter (SS, cell granularity) and SS/CD45. Regions within
the SS vs. CD 14 gates determined the subpopulations of granulocytes, monocytes, and
lymphocytes:

low
(monocytes), and
CD 14neg/S S low (lymphocytes), CD14bnght/ SS

CD14pos/SShlgh (granulocytes). Lymphocyte subsets were determined using the FS/SS
(total leukocyte) gate along with a CD45po7SSlow gate. The instrument was calibrated
with CaliBrite beads (Becton Dickinson) using FACSComp software (Becton Dickinson)
before each analysis. Cells were identified by mouse monoclonal antibodies directly
conjugated to either fluorescein isothiocyanate (FITC) or R-phycoerythrin (PE),
purchased from BD Biosciences, or Cy5-phycoerythrin (Cy5PE), acquired from Caltag
Laboratories (Burlingame, CA). Non-specific staining was determined using the isotype
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controls, mouse mlgGi-FITC and mlgGi-PE, and 5000 lymphocyte events were analyzed
per sample.

2.3. Amyloid precursor protein and amyloid-f3 peptide
Surface expression of APP and intracellular expression of A(3 in lymphocytes and
monocytes were determined using a mouse IgGi monoclonal antibody directed against
the epitope within amino acids L18-R288 or P365-R411 of APP (R&D Systems,
Minneapolis, MN), and a mouse IgGi monoclonal antibody recognizing an epitope within
amino acid residues 1-12 of the A(3 peptide (clone BAM-10, Sigma, Saint Louis, MO).
FITC labeled goat anti-mouse IgG antibody (GAM-FITC; Pierce, Rockford, IL) was used
as the secondary fluorescent label for both surface APP and intracellular Ap. For surface
APP staining, whole blood (0.1 ml) was incubated with primary antibody (0.5 mg/ml) for
20 min. Then cells were washed twice with 2 ml of lx PBS, followed by incubation with
GAM-FITC (1:50 dilution) for 20 min in the dark at RT. Erythrocytes were lysed with 2
ml of lx VitaLyse for 60 min in the dark at RT and centrifuged at lOOOxg for 1 min.
Lysate was decanted, cells were vortexed vigorously to resuspend the pellet, and then
washed with 2 ml of lx PBS, repeating the centrifugation and decanting. Cells were
resuspended in 0.5 ml lx PBS and immediately analyzed by flow cytometry. For staining
of intracellular A(3 peptide, following erythrocyte lysis, cells were fixed and
permeabilized using 0.1 ml of lx PermaCyte-FP (BioE) for 2 h. After fixation, cells were
centrifuged (1000 xg for 1 min) and supernatant decanted. Cells were incubated with the
primary antibody for 20 min, washed twice with 2 ml of lx PermaCyte-FP, and incubated
with the secondary, GAM-FITC, for 20 min. Cells were washed twice with 2 ml of lx
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PermaCyte, centrifuged, resuspended in 0.5 ml lx PBS, and analyzed by flow cytometry.
Electronic gates (FS/SS) were used for analysis of lymphocytes and monocytes, and a
minimum of 1000 monocyte events were required for analysis.

2.4. Statistics
Data for immunophenotypes were evaluated with the non-parametric MannWhitney U test since cell markers are known to have a non-Gaussian distribution
(Lombardi et ah, 1999). The flow cytometry data for APP and Ap expression were
analyzed by both comparing the percentage of cells of a certain population expressing the
marker of interest and comparing the mean fluorescence units of each population. Since
lymphocyte APP expression is known to have a normal distribution (Ledoux et a., 1993;
Pallister et ah, 1997), comparison of APP and A(3 expression between groups was done
using the student’s t test. Data are presented as means ± SEM, and a P value of < 0.05
was chosen to indicate statistical significance. There was no significant difference in
gender distribution as determined by chi square analysis or in age or education as
determined by the student’s t test between MCI subjects and controls. All statistics were
performed using the SPSS 12.0.1 software.

3. Results
3.1. Immunophenotyping
We analyzed the relative percentage of leukocyte subpopulations in circulation,
i.e., lymphocytes, monocytes, and granulocytes, as well as lymphocyte subsets, including
T helper/inducer, T suppressor/cytotoxic, and B lymphocytes in subjects with MCI.
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Compared to healthy elderly controls, the percentage of total lymphocytes was
significantly lower in MCI subjects ip = 0.02, Table 8). By contrast, the proportion of
granulocytes was significantly higher in MCI patients versus controls (p = 0.04). No
difference was seen in the percentage of monocytes between the groups. The relative
proportion of lymphocyte subsets (T and B cells) indicated a trend that approached
statistical significance toward lower percentages of CD3+ cells and CD3+CD4+ cells in
MCI subjects compared to controls. Similarly, the percentage of CD8+ cells and the ratio
of CD4+/CD8+ cells did not significantly differ between the two groups. No correlation
between the proportion of lymphocytes and granulocytes and patient age was seen. Thus,
the percentage of lymphocytes and granulocytes, but not lymphocyte subtypes studied,
were altered in MCI subjects compared to that in controls.

3.2. APP and A(3
We also analyzed APP and A(3 expression on lymphocytes and monocytes from
subjects with MCI compared to elderly controls.

Although a small proportion of

lymphocytes were positive for surface APP expression, both the percentage (9.42% ±
0.79 in controls versus 12.83% ± 1.37 in MCI,/? = 0.01) and mean fluorescence (115.9 ±
5.0 in controls versus 138.9 ± 7.3 in MCI,/? = 0.001) of lymphocytes expressing surface
APP were significantly higher in MCI subjects compared to controls (Figure 10). By
contrast, A(3 expression in lymphocytes did not differ between the two groups.
Monocytes represented approximately 4-11% of PBMCs in both MCI subjects and
controls, and approximately 50% of the monocytes gated showed expression of APP
while nearly 100% had A(3 expression in both subject groups. However, there were no

113

significant differences in the expression of APP or Ap peptide in monocytes between
MCI subjects and elderly controls. Thus, APP expression was increased in lymphocytes
but not monocytes in MCI relative to controls, and Ap expression did not differ between
the two patient groups in either cell type.
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Table 8 Peripheral blood leukocyte subpopulations expressed as a percentage of total
leukocytes (SD) and lymphocyte subpopulations (T lymphocyte subsets and B
lymphocytes) expressed as a percentage of total lymphocytes (SD) in MCI subjects (n =
48) and elderly controls (n =24). * statistically significant, p < 0.05 vs. controls; ns, not
significant.
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CD45bn9ht/SSlow (Lymphocytes)
CD45dim/SShi9h (Granulocytes)
CD45bri9ht/CD14+ (Monocytes)
CDS (T lymphocytes)
CD3CD4 (Helper/inducer T
lymphocytes)
CD3CD8 (Suppressor/cytotoxic
T lymphocytes)
CD4/CD8 ratio (Helper
/Cytotoxic T lymphocytes)
CD19 (B lymphocytes)

MCI subjects
Mean (SD)
25.06 (9.05)*
67.28 (9.61)*
7.33 (2.01)

Elderly controls
P values
Mean (SD)
28.87 (7.97) p = 0.02
64.07 (8.23) p = 0.04
6.72 (1.86) ns

64.64 (10.14)
42.12(14.26)

68.64 (8.00) p = 0.06
48.81 (9.79) p = 0.06

24.55 (17.77)

24.31 (11.74)

ns

2.25 (1.58)

2.53 (1.39)

ns

11.26 (9.58)

10.26(4.60)

ns
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Figure 10. Cell surface amyloid precursor protein (APP) and intracellular amyloid beta
peptide (A(3) expression in lymphocytes and monocytes as percentage of positivelylabeled cells or as mean fluorescence levels in MCI subjects (n = 48) and healthy elderly
controls (n =24). Data are shown as mean (± SEM). * statistically significant, p < 0.05
compared to controls.
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4. Discussion
The purpose of this study was to characterize leukocyte phenotypes and determine
differences in the expression of APP and Ap in peripheral blood cells from MCI subjects
relative to elderly controls. We have found a decrease in the percentage of total
lymphocytes and a concomitant increase in granulocytes, with no change in monocytes,
in MCI subjects compared to controls. The findings support the hypothesis that changes
in certain peripheral immunophenotypes occur in MCI patients.

The decrease in

lymphocytes in MCI subjects is consistent with reports of a decrease in the proliferative
ability of lymphocytes from AD patients compared to controls (Shalit et al., 1995).
Furthermore, our results of increased granulocytes in MCI subjects are in agreement with
the findings of Licastro et al. (1994) who found granulocyte activity to be increased in
AD but not in Parkinson’s disease patients, suggesting an inflammatory state specific to
AD. An increase in oxidative stress and the expression of CD 11b, important in
transendothelial migration, in neutrophils from AD patients compared to controls has also
been reported (Scali et al., 2002; Vitte et al., 2004). We do not know if the increase in
granulocytes we found in our MCI subjects was accompanied by an increase in their
activity since we did not measure granulocyte activity, but our findings of increased
granulocytes give evidence for an early inflammatory state in AD.

Therefore, the

decrease in lymphocytes and elevation in granulocytes in MCI subjects may indicate
changes in the relative balance of immune responses in MCI that could be predictive of
clinical manifestations of the progression to AD.
In another important aspect, the distribution of lymphocyte subpopulations was
similar between MCI and elderly controls. MCI subjects tended to have a lower
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percentage of CD3+ cells (total T lymphocytes) and CD3+CD4+ cells (helper/inducer T
lymphocytes) compared to controls but these did not reach significance. Moreover,
although MCI subjects had a slightly lower proportion of CD4+ cells, we saw no
differences in the percentage of CD8+ cells and the ratio of CD4+/CD8+ cells between
MCI and controls. These results are in agreement with other investigators who have
found no differences in the distribution of CD4+ and CD8+ cells and CD4+/CD8+ ratios
in AD patients compared to controls (Richartz-Salzburger et al., 2006; Ikeda et al., 1991).
Findings that leukocytes express APP have led to studies of amyloid metabolism
in AD patients. Increased expression of APP mRNA and protein in lymphocytes and
monocytes has been demonstrated in AD patients, suggesting that the same alterations in
APP expression leading to amyloid deposition in the brain may be reflected in peripheral
immune cells (Pallister et al., 1996; Jung et al., 1999; Jiang et a., 2003) and/or potentially
be a source for abnormal amyloid deposited in the brain (Allen et al., 1991; Reale et al.,
2005). We investigated APP and Ap expression in lymphocytes and monocytes from
subjects with MCI to determine if similar alterations could be observed in a preclinical
stage of AD. Compared to controls, we found significantly higher lymphocyte APP
expression in MCI subjects. However, the expression of APP and A(3 in monocytes did
not differ between the two groups. Only a small proportion of lymphocytes were positive
for surface APP for both patient groups which is consistent with findings by Bullido et al.
(1996) who demonstrated that B lymphocytes express surface APP while no APP
expression is observed in T lymphocytes. Thus, the lymphocytes staining for APP in our
study are likely to be B lymphocytes, but since we examined total lymphocyte staining
for APP, the determination of the subpopulation of lymphocytes expressing APP must be
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confirmed by costaining for cell specific markers. Increased APP could be a source for
circulating A|3 that may be linked to A(3 deposited in CNS vasculature. In addition to
APP, we also examined intracellular A|3 as increasing evidence suggests that intracellular
A(3 accumulation precedes plaque and neurofibrillary tangle formation and is an early
event in the disease process (Wilson et ah, 1999; Gouras et ah, 2000; Gouras et ah,
2005). Kienlen-Campard et ah (2002) have shown that long term expression of human
APP in rat cortical neurons induce neuronal apoptosis that is dependent on intracellular
but not extracellular Ap. In this study, no differences in intracellular Af3 expression in
lymphocytes or monocytes were found. Increased APP without a concomitant elevation
in A(3 could indicate changes in the processing of APP or an increase in the secreted form
of Ap although this would need to be confirmed as we did not measure secreted Ap.
Moreover, APP and Ap were also measured in granulocytes, as this population showed
an increase in MCI, but no differences were seen between controls and MCI subjects
(data not shown). It remains unclear whether increased APP expression in lymphocytes
from MCI subjects reflects an emerging dysfunction in APP metabolism seen in APP
expressing cells in general, including neurons, in AD or is a causative factor in the
disease. Either way, alterations in peripheral blood cells may prove to be an accessible
biomarker for diagnosis and study as to the mechanisms underlying AD (Jung et ah,
1999).
A limitation to this study is the presence of confounding factors such as
hypertension, diabetes and CHD which have been associated with both dementia (Qiu et
ah, 2005; Bergmann & Sano, 2006) and peripheral immune dysregulation (Aukrust et ah,
2005; Kempf et ah, 2006; Zuliani et ah, 2006) although no differences in their incidence
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between controls and MCI subjects were found. Furthermore, the changes in the
proportions of lymphocytes and granulocytes, and lymphocyte APP expression are
relatively small and may not have immediately apparent clinical consequences in MCI.
However, a chronic imbalance in granulocytes and lymphocytes may predispose to
increased inflammatory responses, and overexpression of APP in lymphocytes, which
may reflect similar processes in the brain, could lead to increased deposition of A(3 and
promote the development of AD pathology. The detection of these changes at a preclinical stage of AD could also aid in the development of biomarkers for AD. However,
the second limitation to this study is the heterogeneity of the MCI subjects as not all of
them will transition into AD. Progression rates from MCI to AD of 10-15% per year have
been reported in several studies (Grundman et al., 2004) but other groups have reported
varying progression rates, such as 5% (Thai et al., 2005). Future studies will be necessary
to determine the specificity of these immune changes in MCI subjects that progress to
AD versus those who remain as MCI.
In conclusion, our results show an alteration in the peripheral immune response in
MCI. Decreased lymphocytes and increased granulocytes in MCI patients compared to
elderly controls may indicate a disturbance in the balance of the immune response in the
preclinical stages of AD. Furthermore, we detected increases in peripheral APP
expression in MCI, a change previously reported in AD. Whether both alterations are a
cause or consequence of disease progression remains to be investigated. These results
have implications in elucidating the role of peripheral immune factors in the pathogenesis
of AD and allowing for monitoring of disease progression and response to therapeutics.
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CHAPTER SIX
ANALYSIS OF BRAIN METAL METABOLISM IN AGED IRP2-/- MICE
Introduction
In addition to the regional iron measurements done on C57BL/6NTac, C57BL/6J,
and IRP2-/- mice at 6, 12 and 24 weeks of age, regional concentrations of total copper
were also measured for the same strains and time points. Perturbations in iron metabolism
should affect the homeostasis of other metals, especially copper, the other redox-active
metal in the brain. Furthermore, a deficiency in neuronal copper is seen in AD, which has
been associated with increased APP expression (Bayer & Multhaup, 2005; Maynard et
al., 2002; White et al. 1999). Additionally, aged IRP2-/- and IRP1+/-IRP2-/- mice, which
develop a more severe form of neurodegeneration (Smith et al., 2004), were examined for
brain levels of loosely bound, non-heme, total iron, and total copper at 12 months of age.
Finally, to complement the finding of axonal degeneration in IRP2-/- mice demonstrated
previously using amino-cupric silver staining (LaVaute et al., 2001), we examined
synaptic density by immunohistochemically staining for synaptophysin.

Materials and Methods
Total copper concentrations in C57BL/6NTac, C57BL/6J, and IRP2-/- mice at 6,
12 and 24 weeks of age were determined according to the protocol used for extracting
and measuring total iron as outlined in the materials and methods section in chapters 2
and 3. Loosely bound, non-heme, total iron and total copper in 12 month old wildtype (n
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= 3), IRP2-/- (n = 2) and IRP1+/-IRP2-/- mice (n = 2) were extracted and measured
according to the methods described in chapters 2 and 3. For synaptophysin
immunohistochemistry, 8-9 month old male wildtype C57BL/6 and IRP2-/- mice (n = 3
for each strain) were anesthetized with Nembutal and cardiac perfused with 20 ml of PBS
to remove blood, followed by 20 ml of 10% buffered formalin. Brains were removed and
fixed in 10% buffered formalin for at least 24 h before they were paraffin embedded and
prepared into 6 pm sections on positively charged slides. Sections were stained with
mouse monoclonal anti-synaptophysin (1:20) purchased from Dako (Carpinteria, CA)
employing the same methods used for IRP2 immunohistochemistry as described in the
materials and methods section of chapter 3.

Results
Total copper was found to increase with age in all strains over a wide range of
regions similar to non-heme and total iron with the highest levels found in the
cerebellum, dorsal striatum and septum (Table 9). The most marked increase in total
copper was observed in the septum where it increased by 24% from 5.1 ± 0.6 pg/g at 6
weeks to 6.4 ± 0.4 pg/g at 12 weeks and by 75% to 11.1 ± 0.7 pg/g at 24 weeks (p <
0.001) in BL/6NTac mice. Furthermore, copper concentrations significantly increased in
the dorsal striatum at 24 weeks compared to 6 weeks, and in the thalamus and brainstem
at 24 weeks compared to 12 weeks. For the BL/6J line, all regions except the cerebellum
and entorhinal cortex exhibited significant increases in the levels of total copper with
development. As with BL/6NTac mice, the most marked increase in copper was found in
the septum. Total copper increased by 64% from 4.5 ± 0.3 pg/g at 6 weeks to 7.3 ± 0.5
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|j,g/g at 12 weeks and by 77% to 13.0 ±1.4 gg/g at 24 weeks (p < 0.001). Similar to
wildtypes, IRP2-/- mice also exhibited increased total copper concentrations with age.
However, whereas the non-transgenics showed a dramatic increase in total copper,
especially in the dorsal striatum and septum between 12 to 24 weeks, copper levels in the
same regions in IRP2-/- mice increased to a far lesser extent. In IRP2-/- mice, copper
levels increased by 26% from 6.9 ± 0.5 pg/g at 12 weeks to 8.7 ±1.0 pg/g at 24 weeks in
the septum (p < 0.01) compared to a 75% and 77% increase in the BL/6NTac and BL/6J
lines, respectively. No differences were found in the levels of any of the iron pools
between aged IRP2-/-, IRP1±/-IRP2-/- and wildtype mice, but copper concentrations
were significantly higher in the olfactory bulb, thalamus and hypothalamus in 12 month
old IRP2-/- and IRP1±/-IRP2-/- mice compared to wildtype (Figure 11). Finally, no
significant differences in immunoreactivity for synaptophysin were seen between IRP2-/and wildtype mice.
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Table 9 Regional concentrations of total copper (presented as mean ± SD) with
development in two non-transgenic mouse lines, C57BL/6NTac and C57BL/6J, and
IRP2-/- mice at 6, 12 and 24 weeks. OB, olfactory bulb; FC, frontal cortex; PC, parietal
cortex; CB, cerebellum; HP, hippocampus; DS, dorsal striatum; VS, ventral striatum; SP,
septum; TH, thalamus; HY, hypothalamus; EC, entorhinal cortex, BS, brainstem. %A,
percentage difference in copper concentration between 6 wk and 12 wk or 12 wk and 24
wk.a p < 0.05 vs 6 wk, h p < 0.01 vs 6 wk,c p < 0.001 vs 6 wk, A p < 0.05 vs 12 wk,e p <
0.01 vs 12 wk//? < 0.001 vs 12 wk.
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Figure 11. Total copper levels in the olfactory bulb, thalamus and hypothalamus in
wildtype, IRP2-/- and IRP1+/-IRP2-/- mice at 12 months of age; significant differences
between mouse strains: * /? < 0.05 vs wt, ** /? < 0.01 vs wt.
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Conclusions
Copper is essential for the proper development of the CNS, and reduced
dopamine has been shown in the striatum of copper-deficient rats (Prohaska & Bailey,
1994; Didonato & Sarkar, 1997; Tarohda et ah, 2004). However, little is known about its
specific roles in the brain. In this study, we demonstrated that levels of total copper in
wildtype and IRP2-/- mice are comparable across different brain regions and increase
with age until 24 weeks when copper concentrations in the cerebellum, dorsal striatum
and especially the septum surpass all other regions. Levels in the septum were almost 2fold higher compared to other regions. However, the increases in the three regions were
to a far lesser extent in IRP2-/- mice, and the balance of iron and copper may be disturbed
in the brains of these mice.
Surprisingly no differences in iron levels were seen in aged IRP2-/- or IRP1+/IRP2-/- mice compared to wildtype, suggesting that the differences observed at a young
age (6 weeks), specifically functional iron deficiency, may have adverse effects in
development that are not apparent in total concentrations at older ages. Higher copper
levels in aged IRP2-/- and IRP1+/-IRP2-/- mice in select brain regions are in contrast to
lower levels of copper in certain regions in young IRP2-/- mice compared to wildtype.
The small number of IRP1+/-IRP2-/- mice available limited our studies to aged mice, but
future studies will be necessary to determine whether the same loosely bound iron
deficiency demonstrated in young IRP2-/- mice could also be seen in young IRP1+/IRP2-/- mice. The lack of differences in synaptic density between wildtype and IRP2-/mice may indicate that synaptic degeneration does not begin until mice are older than 8-9
months as neurodegenerative symptoms are known to worsen with age.

134

References
Bayer, T. A. & Multhaup, G. (2005). Involvement of amyloid beta precursor protein
(AbetaPP) modulated copper homeostasis in Alzheimer's disease. J Alzheimers
Dis 8, 201-206.
DiDonato, M. & Sarkar, B. (1997). Copper transport and its alterations in Menkes and
Wilson diseases. Biochim Biophys Acta 1360, 3-16.
LaVaute, T., Smith, S., Cooperman, S., Iwai, K., Land, W., Meyron-Holtz, E., Drake, S.
K., Miller, G., Abu-Asab, M., Tsokos, M., Switzer 3rd, R., Grinberg, A., Love, P.,
Tresser, N. & Rouault, T. A. (2001). Targeted deletion of the gene encoding iron
regulatory protein-2 causes misregulation of iron metabolism and
neurodegenerative disease in mice. Nat Genet 27, 209-214.
Maynard, C. J., Cappai, R., Volitakis, L, Cherny, R. A., White, A. R., Beyreuther, K.,
Masters, C. L., Bush, A. I. & Li, Q. X. (2002). Overexpression of Alzheimer's
disease amyloid-beta opposes the age-dependent elevations of brain copper and
iron. J Biol Chem 277, 44670-44676.
Prohaska, J. R. & Bailey, W. R. (1994). Regional specificity in alterations of rat brain
copper and catecholamines following perinatal copper deficiency. J Neurochem
63, 1551-1557.
Smith, S. R., Cooperman, S., Lavaute, T., Tresser, N., Ghosh, M., Meyron-Holtz, E.,
Land, W., Ollivierre, H., Jortner, B., Switzer 3rd, R., Messing A., & Rouault, T.
A. (2004). Severity of neurodegeneration correlates with compromise of iron
metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci
1012, 65-83.
Tarohda, T., Yamamoto, M. & Amamo, R. (2004). Regional distribution of manganese,
iron, copper, and zinc in the rat brain during development. Anal Bioanal Chem
380, 240-246.
White, A. R., Reyes, R., Mercer, J. F., Camakaris, J., Zheng, H., Bush, A. L, Multhaup,
G., Beyreuther, K., Masters, C. L. & Cappai, R. (1999). Copper levels are
increased in the cerebral cortex and liver of APP and APLP2 knockout mice.
Brain Res 842, 439-444.

135

CHAPTER SEVEN
GENERAL DISCUSSION
Summary of Findings
This study characterized iron dysregulation and inflammation prior to the onset of
neurodegenerative and clinical symptoms in transgenic IRP2-/- mice and MCI patients,
respectively. We measured the levels of the different pools of iron in the brains of a
mouse model of iron dysregulation dependent neurodegeneration and AD patients at
different stages of the disease. Furthermore, the peripheral immune response was
examined in subjects with MCI, a pre-clinical stage of AD. Results from experiments on
mice in chapter 2 and human studies in chapter 3 both demonstrated a functional iron
deficiency prior to or at the early stages of neurodegeneration. In addition, increased
production of cytokines as well as increases in APP expression was seen in MCI subjects.
Thus, these results support our hypothesis that perturbations in iron and a tendency
towards an inflammatory phenotype can been detected even before the onset of apparent
neurological symptoms.

Functional Iron Deficiency in Neurodegeneration
Studies on IRP2-/- mice in chapter 2 demonstrated that while loosely bound iron
levels remain constant or decrease with age in wildtype mice, they increased in the
ventral striatum, thalamus and whole brain of IRP2-/- mice. This increase in loosely
bound iron appears to arise from low levels of this metabolically active iron pool at 6
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weeks compared to the wildtype mice as concentrations are relatively similar again at 24
weeks across strains. This is in support of previous findings by LaVaute et al. (2001),
who describes axonal degeneration following ferric iron and ferritin accumulation in
white matter tracts of the striatum and thalamus and a decrease in transferrin receptor 1 in
IRP2-/- mice concomitant with a progressive neurodegenerative movement disorder. Our
results support the hypothesis that the neurodegeneration observed in these mice may be
due to a functional iron deficiency from increased iron sequestration into overexpressed
ferritin (LaVaute et al., 2001). During the early stages of normal development, the brain
acquires iron at a high rate which reaches a plateau in adulthood to a low rate that
remains relatively stable throughout the remainder of life in both humans (Hallgren &
Sourander, 1958) and rats (Tarohda et al., 2004). Iron deficiency during this critical
period of early development has been associated with neurological deficits, especially in
cognitive and motor function, persisting until adulthood (Connor et al., 2001; GranthamMcGregor, et al., 2001). The observed deficiency in loosely bound iron in the young mice
may set the stage for the described cognitive deficits in the IRP2-/- mice.
Results of studies on the brains of AD patients in chapter 3 indicated that loosely
bound iron concentrations were significantly decreased in the hippocampal white matter
in mild-moderate and severe AD but not dementia with Lewy bodies (DLB). This may
suggest that alterations in loosely bound iron occurs relatively early in AD and may be
specific to this disease process. Our results are consistent with a previous study that
showed decreased transferrin and iron in AD white matter (Connor et al., 1992) and may
be a cause or consequence of myelin breakdown and oligodendrocyte damage observed
in AD (Bartzokis et al., 2004; Sjobeck & Englund, 2003). Oligodendrocytes have high
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basal metabolism, which is needed for lipid synthesis, and are consequently vulnerable to
oxidative stress. Not surprisingly, these cells contain the highest levels of iron out of all
the cell types in the brain, and up to 70% of brain iron is associated with myelin
(Bartzokis, 2004; Connor, 2004; Zecca et ah, 2004). Iron deficiency causing poor
myelination is associated with mental deficits in children (Bartzokis, 2004), and
decreased myelin basic protein has been shown to correlate with cognitive decline in AD
(Wang et al., 2004). The hippocampus is a region generally affected in the initiating
stages of the disease, and our findings of decreased loosely bound iron in this region
critical for memory may reflect an early loss of oligodendrocytes seen in the brains of
both AD patients and transgenic mice models of AD (El Tannir El Tayara et al., 2006;
Benes, 2004).
In contrast to loosely bound iron, significant differences in non-heme and total
iron were not seen between the patient groups. The accumulation of iron, among other
metals including copper, as well as ferritin in plaques has been consistently shown in the
brains of both AD patients (Miller et al., 2006; Lovell et al, 1998; Grundke-Iqbal et al.,
1990) and transgenic mouse models for AD (El Tannir El Tayara et al., 2006; Falangola
et al., 2005; Vanhoutte et al., 2005). However, measurements of bulk iron levels in the
brain are controversial, ranging from no difference, increase, or decrease in AD brain
compared to controls (El Tannir El Tayara et al., 2006; Hallgren & Sourander, 1960).
Total protein levels have been demonstrated to be significantly decreased in AD frontal
cortex (Loeffler et al., 1995) which may partly explain some of the results when iron
concentrations are measured per milligram of protein. Furthermore, the simultaneous
examination of several iron pools has not been conducted prior to our study, the results of
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which suggest redistribution and sequestering of iron into plaques rather than a general
increase in the bulk tissue of AD brain (Bush, 2003).
In the examination of IRP2 in the same patient groups, we found that expression
was confined to neurons in the gray matter and did not differ between controls, AD and
DLB, in either the frontal cortex or hippocampus. This is inconsistent with findings by
Smith et al. (1998) who found no change in total IRP2 protein in brain homogenates but
strong IRP2 immunoreactivity in a subset of NFTs in AD hippocampus. They suggested
that the IRP2 labeling of only a subset of tangles may be due to either alterations in the
protein or masking of certain of its epitopes at specific stages in disease progression
(Smith et al., 1998). Since they used a polyclonal antibody while we used a monoclonal
antibody developed in our laboratory for this study, our antibody may not have
recognized altered or masked epitopes of IRP2 associated with NFTs. However, the
observed decrease in loosely bound iron in the white matter of the hippocampus in mildmoderate and severe AD is probably not due to decreased expression of IRP2 although
the possibility of a dysfunction in IRP2 remains to be determined.
Total copper levels were significantly lower in the frontal gray matter in severe
AD and DLB compared to controls. The decrease in copper was not seen in mildmoderate AD but only in severe AD, suggesting that this phenomenon may occur at a
later stage in disease progression. Maynard et al. (2002) have found that overexpression
of the A(3 containing carboxyl-terminal fragment of APP in transgenic mice results in
decreased iron and copper in the brain while higher levels of copper were demonstrated
in APP knockout mice (Doraiswamy & Finefrock, 2004; White et al., 1999). Decreased
levels of copper have also been found in AD brain (Deibel et al., 1996) in contrast to the
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increased levels of copper in the CSF and plasma of AD patients (Squitti et ah, 2002;
Basun et al., 1991). It is hypothesized that overproduction of APP and Aj3 pools copper
into the extracellular space from the intracellular compartment and cause a deficiency of
intracellular copper in AD brain (Bayer & Multhaup, 2005; Maynard et ah, 2002).
Moreover, intracellular copper depletion has been reported to downregulate APP gene
expression (Bellingham et al., 2004). Mechanisms similar to that seen in AD brains may
also underlie lower copper levels in DLB, since both diseases share some common
pathologic features. These results lend further support to the hypothesis of dysregulation
of brain iron and copper in AD and related dementias while shedding light on the
timeframe in which these alterations occur in the pathogenesis of the disease. Further
investigation will focus on other dementias such as frontotemporal dementia and cerebral
amyloid

angiopathy

to

determine

the

specificity

of metal

imbalances

in

neurodegeneration.

Inflammatory Phenotype in MCI
Systemic immune changes have been observed in AD patients, including
decreased proliferative ability of lymphocytes and imbalances in cytokine production and
the distribution of leukocyte subpopulations (Richartz-Salzburger et al., 2007; Lombardi
et al., 1999). Peripheral blood cells were immunophenotyped and cytokine release
evaluated in subjects with MCI to test the hypothesis that these systemic changes occur
early in the disease process. Characterizing early events are important in aiding diagnosis
and predicting progression to AD. In our investigation of cytokine production by cultured
PBMCs from healthy elderly controls, MCI and mild AD subjects, we found that levels
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of IL-6, IL-8 and IL-10 were significantly higher in MCI subjects compared to controls
when cells were stimulated with phytohemagglutinin (PHA), but there was no difference
between controls and mild AD patients. However, our findings on mild AD patients must
be interpreted with caution since we only had a small n value. Furthermore, we found a
decrease in the percentage of total lymphocytes and a concomitant increase in
granulocytes, in MCI subjects relative to controls. These results may indicate changes in
the relative balance of immune responses favoring inflammation in MCI subjects that
could be predictive of clinical manifestations in the progression to AD. Additionally, we
found significantly higher lymphocyte APP expression in MCI subjects compared to
controls. Increased APP could be a source for circulating A(3 that may be linked to A(3
deposited in CNS vasculature. It remains to be determined whether increased APP
expression in lymphocytes from MCI subjects reflects an emerging dysfunction in APP
metabolism seen in APP expressing cells in general, including neurons, in AD or is a
causative factor in the disease.
Either way, alterations in peripheral blood cells may prove to be an accessible
biomarker for diagnosis and study as to the mechanisms underlying AD (Jung et al.,
1999). However, follow up data will be necessary to determine whether APP lymphocyte
expression correlates with disease progression in the subset of MCI subjects that progress
to severe AD. Moreover, as not all MCI subjects will eventually develop AD (Grundman
et al., 2004; Petersen, 2004), the heterogeneity of the MCI subjects results in a high
variability within this population and is a limiting factor in this study. Thus, future studies
to specify these immune changes to MCI subjects that convert to AD versus those who
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remain as MCI will be required before such immune parameters, in conjunction with
other diagnostic measures, can be used as biomarkers for AD.

Conclusions
In conclusion, this study has demonstrated that functional iron deficiency is
apparent before or at the early stages of neurodegeneration in certain affected regions of
the brain. The results of this study, among others, support the further investigation of the
role of iron deficiency in neuron injury at the initiating stages of AD. The findings of an
increased tendency toward an inflammatory phenotype and an elevated expression of
APP in the lymphocytes of MCI subjects raise the possibility that peripheral immune
cells can function as a probe to examine pathological processes occurring in the CNS.
Furthermore, early indications of inflammation in MCI warrant the use of NSAIDs as a
possible therapeutic in this pre-clinical stage of AD.
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